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Nearly half of cancer patients are eligible for radiotherapy at least once during the course of 
disease. The current main pillar is photon radiotherapy but particle-based approaches such 
as proton and carbon beams are stepping out of their niche. In contrast to photon 
irradiation, proton irradiation allows to reduce the dose deposited to healthy tissue as well 
as the specific sparing of critical structures. Furthermore, proton irradiation not just exhibits 
superior beam characteristics but also induces a different cellular response. The higher 
linear-energy transfer (LET) of proton beams is predicted to induce more complex DNA 
double-strand breaks which explains the subsequently different recruitment and utilization 
of DNA repair machineries. In detail, an increased necessity and utilization of homologous-
recombination repair (HRR) was observed in response to proton irradiation. As a result, the 
extrinsic abrogation of HRR provides a promising rational to specifically sensitize cancer cells 
for proton radiotherapy. 
In this PhD project, we investigate the combination of HSP90 inhibitor Ganetespib with 
protons administered at a proximal and a distal position in a Spread-Out Bragg peak (SOBP) 
in reference to conventional photon irradiation. HSP90 is a chaperon and upregulated in 
cancer cells due to the elevated intrinsic proteotoxic stress. HSP90 inhibition in turn 
demonstrated to downregulate numerous HRR-relevant proteins such as BRCA1, BRCA2, and 
Rad51 and conclusively impairs HRR. We investigated clonogenic cell survival in A549 non-
small cell lung cancer (NSCLC) and FaDu head and neck squamous cell carcinoma (HNSCC) 
cell lines treated with or without low-dosed Ganetespib and either irradiated with 200kV 
photons or protons at a proximal (LET 2.1keV/µm) or at a distal (LET 4.5keV/µm) position in 
a SOBP. Ganetespib treatment significantly radiosensitized both investigated cancer cell lines 
for SOBP proton irradiation but only negligible when combined with photon irradiation. 
Higher and more persistent protein levels of Rad51 were determined in proton-treated A549 
cells and the downregulation of Rad51 upon Ganetespib treatment confirmed. In 
comparison to photon-irradiation cells, proton-irradiated cells exhibited a more pronounced 
accumulation in S/G2/M phase at 8h and 24h after irradiation. Ganetespib abrogated this 
accumulation and decreased the fraction of cells in S/G2/M phase at each investigated time 
point and conclusively limits the availability of HRR in these cells. Irrespective of the type of 
administered irradiation, a similar number of γH2AX foci was induced and also foci removal 
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was indifferent. Furthermore, foci removal was also not altered by Ganetespib treatment 
despite the observed reduction in Rad51 protein levels and the restricted access to HRR. 
These findings suggest that HRR capacity either remained sufficient or missing HRR capacity 
was replaced by Rad51-independent but more error-prone repair pathways.  
In conclusion, we are the first ones to demonstrate a specific radiosensitization for SOBP 
proton irradiation by HSP90 inhibitor Ganetespib. In both cell lines investigated, RBE 
increases of up to 30% were observed in Ganetespib-treated cells. Additionally, we 
highlighted the role of Rad51 in response to proton radiotherapy. Overall, our generated 
data supports the promising rational of combining SOBP proton radiotherapy with HSP90 
inhibitors and fosters continuing preclinical and clinical investigation.  







Per aspera ad astra 
 
The relief in handing in this thesis and manuscript is immeasurable. This thesis was not just a 
challenge in regards of cancer biological questions but also a logistical and a personal one. 
Nevertheless, a huge number of people supported me during this long and cumbersome 
path. 
The first ones to mention are the other early-stage researchers involved in the ITN Radiate 
program. Regular meetings throughout Europe allowed us to grow on each other’s 
experience and this accumulation of open minds fostered friendship that goes far beyond 
business networking. I also want to thank Dr. Nagma Khan who managed this sack full of 
fleas while always providing each of us with an open ear and useful advice.  
In addition, I want to thank the members of the group headed by Prof. Dr. Pruschy who 
allowed me to reflect on and proceed with my work, kept me mentally sane and my spirit 
alive. I especially want to acknowledge Dr. Ivo Grgic who provided me with asylum in F-Lab 
and supported me during unpleasant times. I also want to thank Dr. Philip Knobel and 
Verena Waller who assisted me with flow cytometry and provided me with critical thoughts 
regarding my data. Last but not least, I also want to thank Erica Faccin who pushed urgent 
orders and investigated on delayed ones while always having a smile on her face and a 
positive attitude in her mind.  
Needless to say, I also want to thank the people involved in my work at MedAustron. Dr. 
Sylvia Gruber, Elisabeth Mara and Karin Posch not just hosted but included me and 
supported me with cell culture but also with planning the experiments and analysing the 
obtained data. This little bubble in Austria allowed me to implement my own ideas and 
conduct research in proton irradiation in an incredibly inspiring environment. Conclusively, I 
also want to mention Anton Kerschbaum who assisted me in understanding the basics of 
proton delivery and interactions and represents the scientifically open and curious 
environment at the MedAustron.  
Most importantly, I want to acknowledge my parents. They not just supported me during my 
childhood and education but were truly involved in this project. I was able to stay at my 
parents` house and use my dad`s car for free. Without this support (and the wake-up calls at 
3 in the morning on a Sunday) I would not have been able to be at the proton shifts in 
Wiener Neustadt and conduct my project in this exciting and outstanding field of research. 




List of Abbreviations 
CTV  clinical target volume 
dCDP  deoxycytidine diphosphate 
dCTP  Deoxycytidine triphosphate 
DNA  deoxyribonucleic acid 
dNTP  deoxynucleoside triphosphate 
DSB  double-strand break 
dsDNA  double-stranded DNA 
G1/S/G2/M phase  phases of cell cycle 
HDACi  histone deacetylase inhibitor 
HNSCC  head and neck squamous cell carcinoma 
HPV  human papillomavirus  
HRR  homologous recombination repair 
HSP90  heat shock protein 90 
HSP90i0  HSP90 inhibitor 
LET  linear energy transfer [keV/μm] 
LINAC  linear accelerator 
MDSC  myeloid-derived suppressor cells 
MMEJ  microhomology-mediated end joining 
MMR  mismatch repair 
NER  nucleotide excision repair 
NGS  Next-Generation Sequencing 
NHEJ  non-homologous end joining 
NSCLC  non-squamous cell lung carcinoma 
OAR  organ-at-risk 
PD-L1  programmed death-ligand 1 
PMMA  poly(methyl methacrylate) 
PTV  planning target volume 
RBE  relative biological effectiveness 
SOBP  Spread-Out Bragg peak 
ssDNA  single-stranded DNA 
TAM  tumor-associated macrophages 
Treg  T regulatory cells 
WHO  World Health Organisation 
wt /mutTP53  wild type / mutated TP53 






Table of Contents 
1. Introduction ......................................................................................................................10 
1.1 Cancer ........................................................................................................................10 
1.1.1 Carcinogenesis and the Global Incidence of Cancer ............................................10 
1.1.2 Hallmarks of Cancer .............................................................................................12 
1.1.2.1 Sustaining Proliferative Signaling ....................................................................... 12 
1.1.2.2 Evading Growth Repressors ............................................................................... 13 
1.1.2.3 Resisting Cell Death ............................................................................................ 14 
1.1.2.4 Enabling Replicative Immortality ....................................................................... 15 
1.1.2.5 Inducing Angiogenesis ........................................................................................ 16 
1.1.2.6 Activating Invasion and Metastasis .................................................................... 17 
1.1.2.7 Genome Instability and Mutation ...................................................................... 18 
1.1.2.8 Tumor-Promoting Inflammation ........................................................................ 19 
1.1.2.9 Reprogramming Energy Metabolism ................................................................. 20 
1.1.2.10 Evading Immune Destruction ........................................................................... 21 
1.2 Cancer Treatment .......................................................................................................22 
1.2.1 Cancer Screening and Diagnostic ........................................................................22 
1.2.2 Surgery .................................................................................................................24 
1.2.3 Chemotherapy ......................................................................................................24 
1.2.4 Immunotherapy ....................................................................................................26 
1.2.5 Radiotherapy ........................................................................................................29 
1.2.5.1 History of Radiotherapy ..................................................................................... 29 
1.2.5.2 Physical basics of radiotherapy .......................................................................... 29 
1.2.5.3 Brachytherapy .................................................................................................... 30 
1.2.5.4 External Beam - Photon therapy ........................................................................ 30 
Physics and Interactions of Photons .............................................................................. 30 
Clinical application, generation and instrumentation ................................................... 32 
1.2.5.5 External Beam - Proton therapy ......................................................................... 34 
Differences in Photon and Proton Physics ..................................................................... 34 
Clinical application, generation and instrumentation ................................................... 36 
1.2.5.6 Differences Photon versus Proton radiotherapy ............................................... 38 
1.3  The 5 R`s of Radiotherapy .....................................................................................40 
1.3.1. Radiosensitivity ...................................................................................................40 
1.3.2 Redistribution .......................................................................................................40 
1.3.3 Reoxygenation .....................................................................................................41 
1.3.4 Repopulation ........................................................................................................42 
9 
 
1.3.5 Repair ...................................................................................................................42 
1.3.5.1 NHEJ .................................................................................................................... 44 
1.3.5.2 HRR ..................................................................................................................... 44 
1.3.5.3 Pathway choices during DNA DSB repair ........................................................... 45 
1.4 Difficulties of cancer therapy and overcoming approaches ..........................................46 
1.4.1 What is the tumor? ...............................................................................................46 
1.4.2 Normal tissue toxicity ............................................................................................47 
1.4.3 Where is the tumor located? .................................................................................47 
2. Aims of the study ..............................................................................................................49 
3. Results .............................................................................................................................50 
3.1 HSP90i by Ganetespib selectively radiosensitizes cancer cells for proximal and distal 
Spread-Out Bragg peak (SOBP) proton irradiation ...........................................................50 
3.2 Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific 
DNA Repair Dependencies ...............................................................................................86 
3.3 The Relative Biological Effectiveness of Proton Irradiation in Dependence of DNA 
Damage Repair .................................................................................................................94 
3.4 Investigating the impact of alpha/beta and LET on RBE in scanned proton beams: an 
in vitro study ................................................................................................................... 104 
3.5 Proton irradiation increases the necessity for homologous recombination repair along 
with the indispensability of non-homologous end joining ................................................. 132 
4. Discussion ...................................................................................................................... 158 
4.1 Current Proton Radiotherapy .................................................................................... 158 
4.2 The role of DNA repair in response to proton radiotherapy and how to modulate it ... 158 
4.3 Context and clinical relevance of this study ............................................................... 161 
5. Outlook ........................................................................................................................... 163 
Table of References - Thesis .............................................................................................. 165 
Table of Figures -Thesis ..................................................................................................... 172 







1.1.1 Carcinogenesis and the Global Incidence of Cancer  
Cancer, malignancies, tumor stage, or metastasis are words describing a disease and its 
features and impose an imminent negative connotation. Cancer is a group of disease 
affecting all groups of people worldwide independent of age, wealth or country and is 
becoming more and more relevant in an aging population. While tremendous advantages in 
versatile clinical fields such as antibiotics, surgery or vaccines have extended the overall life 
expectance, cancer remains a threat. The mortality rates of appendicitis, infected teeth, pox 
or tetanus is marginal in developed countries. Unfortunately, these rates remain high for 
lung, pancreas or oesophagus cancer and thus illustrate the urgent demand for a deeper 
understanding and novel treatment approaches. To further elaborate on this demand, open 
access global statistics collected and provided by the IARC (see Error! Reference source not f
ound.) illustrate the vast numbers of patients worldwide as well as cancer sides with a worse 
outcome than others.  
Table 1 Global cancer incidence and mortality rates 2018 (modified from [1]) 
More than half of cancer patients will succumb to their disease with lung tumors at a high 
incidence as well as mortality rate (84.1%). Breast cancer on the other hand also occurs at high 
rates but the mortality rate (30.0%) is fortunately lower as for liver (92.9%) or stomach cancer 
(75.7%). 
 
  Incidence rate Mortality rate Estim. risk of death 
Total 18.078.957 100.0% 9.555.027 100.0% 52.9% 
Lung 2.093.876 11.6% 1.761.007 18.4% 84.1% 
Breast 2.088.849 11.6% 626.679 6.6% 30.0% 
Colon/Rectum 1.849.518 10.2% 880.792 9.2% 47.6% 
Prostate 1.276.106 7.1% 358.989 3.8% 28.1% 
Stomach 1.033.701 5.7% 782.685 8.2% 75.7% 
Liver 841.080 4.7% 781.631 8.2% 92.9% 
Oesophagus 572.034 3.2% 508.585 5.3% 88.9% 
Cervix uteri 569.847 3.2% 311.365 3.3% 54.6% 
Thyroid 567.233 3.1% 41.071 0.4% 7.2% 
Bladder 549.393 3.0% 199.922 2.1% 36.4% 
Non-Hodgkin 
Lymphoma 
509.590 2.8% 248.724 2.6% 48.8% 
Pancreas 458.918 2.5% 432.242 4.5% 94.2% 
Other 5.668.812 31.4% 3.302.301 34.6% 58.3% 
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These cancer cases provide an overview about global case numbers but there are differences 
between sexes, age groups, race and global region. The difference between sexes in cancer 
incidence and mortality is also illustrated in a graph provided by the open access World 
Cancer Report 2014. 
Figure 1 Illustration of the global incidence and mortality rate (per 100.000) in the 
respective sexes in 2012 [2] 
A strong deviation of cancer incidence can be found between the sexes with usually higher 
incidence rates in man than woman. These deviations are also apparent in different ethnic 
groups, regions and age groups but not illustrated here due to simplicity.  
 
Aggravatingly, these incidence numbers are expected to rise to 25 million annual cases in the 
next two decades which is based on a growing as well as aging population. Despite all 
efforts, risk factors such as infectious disease or low food quality persist in low developed 
regions and/or got replaced by the contradictory risk factors of an industrial lifestyle such 
as high caloric diet, obesity, and reduced exercise.[3-5] In addition, tobacco consumption is 
persisting or increasing in low and middle income countries while fortunately having peaked 
in high income countries.[6]  
Improvements such as HPV vaccination [7, 8], stricter ruling to reduce tobacco as well as 
alcohol consumption and a reversal of the industrial lifestyle with a more balanced diet and 
exercise [9] could be a huge game changer and reduce cancer risk, morbidity and mortality 
as well as the risk for versatile other accompanying disease. Nevertheless, improvements in 
anti-tumor therapy will be essential to reduce the public and personal burden of cancer 
which occurred despite preventive efforts or just by “bad luck”. 
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1.1.2 Hallmarks of Cancer 
The conversion from a normal cell towards a pathologically relevant neoplastic phenotype 
which ultimately becomes malignant and metastasises is a multistep process of highly 
diverse developmental patterns. In 2000, Hanahan and Weinberg published a system which 
attempted to organize this multifarious processes by defining hallmark capabilities.[10] 
These initially 6 hallmarks were expanded to 10 in 2011 by the same authors due to 
increasing knowledge in cancer biology.[11]  
The purpose of the following paragraphs is to bring all readers on the same page and either 
introduce or refresh certain topics and features of cancer. I therefore intend to provide an 
overview of these hallmarks, their role in tumorigenesis as well as their significance for 
choice of therapy.  
1.1.2.1 Sustaining Proliferative Signaling 
One of the most obvious features of cancer cells is their capability to maintain a continuously 
proliferative phenotype. Normal cells receive versatile cues from their environment such as 
growth factors in a paracrine context. Versatile known and unknown factors are part of this 
signalling and control growth factor release, sequestration, degradation or the final response 
by the influenced cell. This complex regulatory network may be corrupted by cancer cells by 
simply producing growth factor ligands themselves or stimulating normal cells to do so. This 
provides cancer cells with a proliferative signalling in an autocrine or paracrine manner, 
respectively. Cancer cells can also receive increased proliferative signalling by upregulation 
of receptors, rendering these cells hypersensitive for defined ligands, or alterations within 
the receptor structure resulting in the continuous signalling of such. These proliferative 
signalling may also be induced by alterations in downstream signalling proteins such as 
KRAS, BRAF or PI3K.[12, 13] In addition, not just activating events but also abolishing the 
action of negative regulators can result in cell proliferation. An example of such abrogated 
negative regulator may be PTEN which is involved in downregulating PI3K and AKT signalling 
and thus limiting tumorigenic signalling.[14, 15] Nevertheless, cells with excessively high 
proliferative capacity may still sense their corrupted state by feedback loops and undergo 
oncogene-induced apoptosis or senescence.[16, 17] This demonstrates the nature of 
excessively high proliferative signalling as two-edged sword with aggressive cellular 
expansion and detrimental cellular stress as the extremes of the scale.  
A typical example for a constitutively activated pathway is the mutation of BRAF in 
melanoma. The substitution of glutamic acid for valine at the 600th codon (V600E) results in 
a constitutive activation of BRAF and is present in 40 to 60% of melanomas.[18] Due to the 
exclusivity of V600E-mutated BRAF in tumor cells, this kinase is an outstanding target for 
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inhibitors which interfere with tumor signaling but theoretically not interfere with normal 
cells.  
Vemurafenib, an inhibitor of aforementioned V600E-mutated BRAF, can be orally 
administered and demonstrated its efficacy in multiple clinical trials. Vemurafenib induced 
partial or complete response in V600E-mutated melanoma patients with response rates of 
48 to 69% and improved overall and progression-free survival.[18, 19] Due to these 
tremendous results, Zelboraf (Vemurafenib) received marketing authorization in 2011 by the 
FDA and 2012 in the EU.[20, 21]  
Another example of cancer cell growth signal inhibition is Imatinib. Imatinib is a kinase 
inhibitor targeting the cancer-associated fusion protein BCR-ABL [22] but also platelet-
derived growth factor receptor (PDGFR).[23]  The aforementioned fusion protein BCR-ABL is 
the result of a chromosome translocation between chromosomes 9 and 22 and results in the 
so called Philadelphia chromosome (a shortened chromosome 22). This translocation results 
in an elevated tyrosine kinase activity and is present in more than 90% of chronic 
myelogenous leukemia and some patients with acute leukemia. These clonally expanded 
cancer cells are more dependent on specific driver proteins and thus strongly respond to 
inhibition of such while normal cells receive signaling cues from versatile pathways and are 
thus less dependent. In conclusion, the improved patient outcome was demonstrated in 
clinical trials [24] and resulted in the approval of Gleevec (Imatinib) in 2001 by the FDA for 
multiple neoplastic entities such as leukemia or gastrointestinal stromal tumors.[25] 
Versatile other drugs also interfere with more or less tumor-specific growth signaling 
pathways such as Erbitux (Cetuximab) preventing ligand binding to EGFR [26, 27], Xalkori 
(Crizotinib) administered against ALK positive NSCLC [28-30], or Tarceva (Erlotinib) 
interfering with the kinase activity of EGFR. [31, 32] 
These drugs can prevent the transmission of growth signals by targeting the extracellular 
part of receptor kinases and preventing ligand binding in case of antibodies and their 
fragments. Small molecule drugs on the other hand mostly block intracellularly the receptor 
tyrosine kinase activity.  
1.1.2.2 Evading Growth Repressors 
Negative regulators of cellular proliferation are important throughout the whole existence of 
the organism and act as safety switches and way to clear unwanted cells may it be because 
of virus infection or tissue remodelling. Moreover, these negative signals also prevent 
unwanted proliferation of intrinsically deregulated cells and thus act as tumor suppressors. 
The most famous of these tumor suppressors are TP53 and RB. 
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RB (retinoblastoma protein) is a protein involved in steering the cell cycle.[33, 34] RB 
prevents cyclin E and A synthesis by repressing E2F-dependent transcription via recruitment 
of histone deacetylases (HDAC) and thus prevents entry into S phase.[35] Mitogenic 
signalling on the other hand induces the synthesis of cyclinD which forms a complex with 
CDK4/6 and finally deactivates RB by phosphorylation to pRB and thus triggers the cell to 
progress into S phase. In conclusion, abolishing RB function by inherited or acquired loss-of 
function mutations as well as hyperactivation of the cyclinD/CDK4/6 complex obviously 
abrogates this regulatory function. While RB may be described as the gate keeper of the cell 
cycle, TP53 is often described as the guardian of the genome.  
For TP53 action, it must be stabilized, bind to DNA in a sequence-specific manner, and 
transcriptionally activate target genes.[36] In a healthy cell, TP53 is continuously produced 
but also continuously ubiquitinylated by MDM2 and thus marked for proteasomal 
degradation. Cellular stress such as DNA damage results in the activation of kinases such as 
ATM, ATR, CHK1, and CHK2 which in turn phosphorylate TP53 and this way stabilize TP53. As 
an example, TP53 then can induce transcription of p21 which is an inhibitor of CDKs or it 
represses CDC25 and thus arrests cell cycle.  
Needless to say, these processes are highly complex and interconnected but already single 
missense point mutations for example in the DNA binding region of TP53 can cause an 
imbalance in this system and are a frequent event in tumors. This illustrates the necessity to 
overcome this growth repression during tumorigenesis to become pathologic while 
transformed cells that retain this control mechanism are unlikely to be ever recognized.  
Another pathologic condition which abrogates these growth suppressors is HPV 
infection.[37] HPV virus can introduce the protein E6 which interacts with TP53 and initiates 
its degradation. Another protein introduced by the virus is E7 which competes with E2F for 
RB protein and thus releases E2F from repression and abrogates RB function.  This 
inactivation of checkpoints and regulatory pathways clearly states the tumorigenic nature of 
HPV infection which is coherently considered to be involved in nearly all cervical cancer, 90% 
of anal cancer, 40% of penile, vaginal and vulvar cancers as well as 25% of oral cavity and 
35% of oropharyngeal cancers.[38] 
Fortunately, prophylactic vaccines against HPV such as Gardasil are spreading globally and 
could reduce cancer incidence in the upcoming generation independent of sex or 
socioeconomic status. [39, 40] 
1.1.2.3 Resisting Cell Death 
Similarly to overcoming growth repressors, cancer cells also need to overcome cell-death-
inducing signalling.  
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Cell death is regulated by versatile proteins sensing and translating external and internal 
signal cues. This balance between pro- and anti-apoptotic signals shifts and triggers 
apoptosis by elevated oncogenic signals, DNA damage due to hyperproliferation or FasL in 
the cellular environment as well as versatile other factors.[11, 41] To specify, anti-apoptotic 
Bcl-2 and further proteins can sequester pro-apoptotic Bax and Bak which are located in the 
outer mitochondrial membrane. A relieve from inhibition therefore results in the disruption 
of the mitochondrial membrane and the release of cytochrome c which in turn activates a 
cascade of caspases. These caspases ultimately trigger apoptosis via their proteolytic 
activity.  
Crosstalk between cell death and growth repression are evident with TP53 as illustrative 
example. In addition to arresting the cell cycle, stabilized TP53 can also trigger apoptosis.[36] 
TP53 can activate genes and proteins such as Bax, CD95 (Fas), PUMA, and a vast number of 
other pro-apoptotic factors as well as inducing mitochondrial outer membrane 
permeabilization and thus initiating the release of pro-apoptotic factors from the 
intermembrane space. Conclusively, TP53 dysfunction by mutation or degradation also 
abolishes this cell-death-inducing pathway. A similar non-responsive phenotype can be 
achieved by overexpression of anti-apoptotic (Bcl-2) or downregulation of pro-apoptotic 
factors (Bax, PUMA).  
1.1.2.4 Enabling Replicative Immortality 
Normal cells can only replicate for a predefined number of cycles until they will run into 
senescence.[11, 42] This cellular replication limit was established against the dogma at the 
time in 1961 by Leonard Hayflick und is thus called Hayflick limit. Cells in senescence are 
non-replicative but viable while cells ignoring this limit are expected to run into cellular 
crisis. 
These effects can be explained by telomeres and their length at the end of 
chromosomes.[43] Repetitive terminal DNA sequences enable the DNA to form loops and 
thus hide and protect the DNA ends from unwanted “repair” and ligation with other DNA 
fragments. The reason of telomere shortening is based on the process of DNA replication 
during S phase and termed end-replication problem.[42] The DNA polymerizing protein 
complex cannot assemble right at the end of the DNA strand but requires a certain length of 
DNA to assemble to. Therefore, the 3’ end of the lagging DNA is used for assembly, lies 
upstream the polymerization site and is conclusively not replicated but lost. This loss in 
telomeric DNA shortens the telomeres with each DNA replication cycle and functions as 
intracellular counting mechanism.  
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Cells incapable of restricting cell replication will run into cellular crisis and shorten their 
telomeres until DNA looping and thus protection is abolished. These unprotected DNA ends 
are mistaken by DNA repair proteins and can be ligated by processes such as Non-
Homologous End Joining (as described in 1.3.5 Repair). Needless to say, unintended ligation 
of chromosome ends can result in dicentric chromosomes which in turn can induce mitotic 
arrest, aneuploidy, and genomic instability and apparently threaten the cell viability. 
A protein to counteract this counting mechanism and cellular crisis is telomerase which can 
add telomeric repeats to the DNA ends. Throughout the organism, telomerase activity is 
highly regulated and almost absent in normal differentiated cells but high in cells which are 
determined for infinite replication such as stem cells and germ cells.[44, 45] On the other 
hand, the vast majority of 85-90% of cancer cells gained a high telomerase activity to 
overcome prementioned obstacles.[43] This mechanism of replicative immortalization and 
the high frequency it occurs in cancer cells demonstrates its hallmark role and how 
detrimental these obstacles and how essential bypassing is. 
1.1.2.5 Inducing Angiogenesis 
While neovascularization, the assembly and formation of new vessels, is limited to 
embryogenesis, angiogenesis, the sprouting of vessels from existing ones, persists 
throughout lifetime. Angiogenesis is a regular process during wound healing and female 
reproductive cycling but otherwise quiescent.  
Due to the increasing demand of nutrients and oxygen by hyperactive and proliferative 
tumor cells, the supply of such becomes a growth limiting factor. Attracting blood vessels to 
provide a sustainable supply is essential to become pathological while lesions incapable to 
do so will remain widely unrecognized.  
Vascular endothelial growth factor (VEGF) family is a key player for blood vessel growth as 
well as homeostasis and gene expression can be upregulated by hypoxia and HIF-1 and HIF-2 
[46, 47] as well as oncogenic signalling.[48-50] Due to this imbalanced chronically activated 
angiogenesis, these newly formed vessels are commonly distorted, enlarged and/or 
immature which results in erratic blood flow, leakiness and haemorrhage.  
Therefore, angiogenesis and blood vessel formation is an obvious clinically relevant target 
for anti-cancer therapy. Bevacizumab, clinically known as Avastin, is an antibody 
sequestering VEGF and has proven its efficacy in versatile clinical trials.[51] It received 
marketing authorization by the FDA in 2004 [52] and the EMA in 2005 for the treatment of 
cancers originating at sites such as colon, rectal, breast, lung, kidney, ovarian, fallopian tube 
and cervix.  
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Also radiotherapy interacts with angiogenesis and oxygen supply (as discussed in 1.3.3 
Reoxygenation) by inducing vessel normalization and thus improved tumor perfusion. In 
addition, tumor vessel dysfunction can also limit delivery of small-molecule 
chemotherapeutics. On the other hand, vessel leakiness may be exploited by the enhanced 
permeability and retention (EPR) effect by utilizing nanoparticles for drug delivery 
approaches such as pegylated liposomes.[53-55] Nanoparticles are less probable to 
extravasate through a mature continuous endothelial layer while the wide fenestration in 
immature tumor-associated blood vessels enables the entry into the tissue and the targeted 
release of the cytotoxic cargo. This effect not just increases the uptake of drug into the 
tumor but also limits the uptake into healthy tissue. 
1.1.2.6 Activating Invasion and Metastasis 
Pathologically growing cancer cells ultimately require space for their proliferative 
phenotype. In differentiated epithelial cells, as progenitors of carcinoma and surrounding 
tissue, E-cadherin and EpCAM may restrict the available space by tight adhesion between 
cells or by the engulfing effect of dense extracellular matrix (ECM).[11, 56] The loss of cell 
adhesion molecules such as E-cadherin is a feature of epithelial-mesenchymal transition 
(EMT) in cancer cells which results in a more motile and invasive phenotype. EMT is 
considered a pro-metastatic event and describes versatile possible changes in cytoskeletal 
components, reassemble of cell-cell contacts and cell motility but also gene expression and 
exocytosis of altered ECM components. Factors involved in the onset of EMT are versatile 
and include Wnt, Notch, hedgehog, cytokines and as most prominent one TGF-β. To increase 
complexity, some metastatic cancer lesions revert to an epithelial phenotype via 
mesenchymal-epithelial transition (MET) while others retain a mesenchymal phenotype and 
thus question the role of MET in metastasis establishment and growth.[57] 
In addition, clinical patterns of cancer spreading can also be correlated to patterns in non-
coding RNA networks such as miRNA, lncRNA, and circRNA.[58] Peritoneal spreading is a 
common symptom in ovarian cancer patients and present with a miliary (vast numbers of 
small millet-like lesions) or non-miliary (few but bulky lesions) pattern. Data suggested EMT 
(-MET) being more relevant for bulky non-miliary lesions as well as a possible spreading via 
the blood/lymphatic system in manner of a regular distant metastasizing. On the other hand, 
miliary-spreading tumor cells retain their epithelial phenotype and globally decrease gene 
expression by enhanced miRNA regulation and as a result are more adapted for spreading 




As enabling factor of invasion and metastasis, the degradation of extracellular matrix and 
membranes should not remain undiscussed.[59-61] The process of ECM degradation is 
important for repair, development and growth of normal tissue but being hijacked by cancer 
cells. A famous family of proteases, matrix metalloprotease (MMP), is commonly 
overexpressed in various cancers and associated with tumor invasion, metastasis and a poor 
prognosis. These endopeptidases degrade essentially all ECM components such as collagen 
of various types, laminin, and fibronectin. Precursor MMPs are extracellularly activated by 
proteolysis but MMP activity can also be dampened by TIMPs (tissue inhibitors of 
metalloproteinases) expressed by tumor or host cells. While MMPs are proven to facilitate 
cell motility and metastasis, TIMPs demonstrated to reduce invasion and metastatic 
capacity. Moreover, MMPs may not only be expressed in tumor cells themselves but can be 
induced in fibroblasts by tumor-cell-derived factors.  
As already prementioned, not only tumor cells themselves determine invasiveness but also 
accompanying cells such as fibroblasts and pericytes.[62] As an example, cancer-cell-
secreted PDGF-BB was found to induce pericyte-fibroblast transition (PFT) in pericytes which 
in turn gain mesenchymal features and expressed stromal fibroblasts and myofibroblasts 
markers. Pericytes transformed in this manner were strikingly found to promote tumor 
dissemination and invasion. This clearly states the need to not just investigate tumor cells 
but also take accompanying cells and the tumor microenvironment into account. 
1.1.2.7 Genome Instability and Mutation 
In regular cells, mutation rate is kept at a low sustainable rate by versatile genome 
maintenance systems. These are commonly abrogated in cancer cells to foster the acquiring 
of essential mutant genes and in conclusion facilitate tumorigenesis. As a result, the 
mutational burden in a tissue correlates with the cancer incidence rate in it. [63]  
High mutation rates are based on dysfunctions in DNA repair, DNA modifications or during 
DNA replication.[64] Additionally, mutation rates can also be increased by external factors 
such as tobacco smoke, exposure to ultraviolet light and ionizing radiation, or food borne 
mutagens such as polycyclic aromatic hydrocarbons.[65, 66]  
The prevalence of mutations is highly variable between and within cancer subtypes and can 
range between 0.001 to 400 mutations per megabase of DNA.[67] Factors such as age 
relates into this with childhood cancers usually carrying fewer mutations while chronic 
mutagen exposure explains the high mutation prevalence in lung cancer and melanoma. An 
example for deviations in mutation rate within cancers can be found in prementioned lung 
cancers. NSCLCs of smokers exposed to mutagens demonstrate a 10-fold higher mutation 
rate than NSCLCs in never-smokers.[68]  
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In addition to higher mutation rates, the type of mutation induced also correlates with the 
carcinogen exposed to.[69] As an example, C→A mutations are frequent in lung cancer due 
to polycyclic aromatic hydrocarbon exposure from tobacco smoke while melanoma show a 
high frequency of C→T mutations induced by misrepair of UV-induced DNA damage. These 
findings can be summed up to a subset of approximately 140 genes being defined as 
promoting tumorigenesis when mutated with tumors typically displaying 2 to 8 of these 
driver mutations.[70]  
Increased mutation rates can also be inherited with BRCA1 and BRCA2 as most well-known 
gene defects. BRCA1 and 2 are key players in maintaining genetic integrity and DNA repair 
(in detail at 1.3.5 Repair) and germline mutations go along with a drastically increased 
lifetime risk of developing breast or ovarian cancer.[71-73] Interestingly, upon treatment 
with DNA damaging drugs, which BRCA1/2 deficient cancer cells are sensitive to, a selection 
for cancer cells which regained BRCA1/2 can be observed.[74] This reversion mutation can 
be seen as resistance mechanism but also demonstrates that genome instability may 
promote tumorigenesis at an early stage but becomes obsolete in an established cancer 
lesion.  
Another inherited repair deficiency as an example is Xeroderma pigmentosum.[75] This 
disease originates from a deficiency in Nucleotide Excision Repair (NER) by mutations in 
essential repair proteins. Symptoms include neurological impairments but also 
hypersensitivity to UV-light-induced DNA lesions and thus a 1000-fold increased risk for skin 
cancers. Preventing UV light exposure is a preventive measure but life expectancy is 
nevertheless drastically reduced.   
In summary, genome instability as newly added hallmark is considered to play an enabling 
role in providing cancer cells with vast numbers of mutations and as a result the chance to 
gain new hallmark capabilities, adapt to an altered environment or resist a therapy.[76] 
Obviously, this hallmark is a double-edged sword and can also cause detrimental gene loss 
and cell death. As long as this balance remains more or less positive within the tumor and 
more than half of the daughter cells are viable, it may slow down cancer progression in 
short-term but in long-term it increases the clonal landscape and accelerates the selection 
for more aggressive/resistant/proliferative phenotypes.  
1.1.2.8 Tumor-Promoting Inflammation 
Inflammation can play a major role for tumorigenesis.[11] During normal immune response, 
alarm signals such as invading microbes or tissue damage will alert versatile immune cells 
which help to clear the area of pathogens and secrete factors to activate epithelial cells.[77] 
This secretion accelerates the repair of dysfunctional barriers before the immune response 
20 
 
converts back to homeostasis. In tumorigenesis, not a microbe but oncogenic events can 
lead to epithelial dysfunction. The triggered immune response thereafter may not remove 
the transformed cells but nevertheless provide cytokines and inflammatory factors which as 
a result drive tumor proliferation instead of tissue regeneration.  
In detail, the inflammatory environment can be induced externally by local tissue damage 
such as chronic inhalation of small particles like asbestos which in turn triggers lung and 
airway inflammation. [78] Asbestos-exposed tissue is known to recruit macrophages which 
interact with the carcinogenic fibers, release IL-1β and as a result increase mesothelial 
proliferation. In addition to cytokines released, also reactive oxygen species (ROS) are set 
free which fosters mesothelial cell transformation (see also 1.1.2.7 Genome Instability and 
Mutation). This unwanted ROS release is based on the length of the inorganic asbestos 
fibers which cannot be fully phagocytosed and engulfed by the macrophages and thus cause 
accidental leakage into the surrounding tissue.  
The inflammatory environment can also be systemic when caused by internal cues such as 
obesity.[79] Adipocytes are becoming hypertrophic and die during weight gain which shifts 
the previously type 2 (anti-inflammatory) cytokine rich environment towards a type 1 (pro-
inflammatory) state with increased TNF, IFN-γ, and IL-1β levels. Overnutrition is also found 
to suppress anti-inflammatory signaling in classic dendritic cells which results in dendritic cell 
activation and continuous antigen presentation, triggering a T-cell-mediated response and in 
turn T cell exhaustion due to continuous activation.  
Strikingly, also metastasis is facilitated by obesity-induced inflammation.[80] Lung 
neutrophilia induced by obesity fosters breast cancer metastasis which could be reverted by 
weight loss. This effect was demonstrated to be linked to elevated GM-CSF and IL-5 levels in 
obese mice and clearly demonstrates a link between inflammatory phenotypes and cancer.  
These inflammatory patterns in cancer induction are versatile and further prominent 
examples of inflammation-promoted tumors are inflammatory bowel disease, chronic 
hepatitis, Helicobacter-induced gastritis, and schistostoma-induced inflammation of the 
bladder.[77] 
1.1.2.9 Reprogramming Energy Metabolism 
Deregulated and high proliferation within cancer obviously also requires an altered 
metabolism to fuel tumor growth.[11] Already in 1920, an altered metabolism in cancer cells 
was described by Otto Warburg.[81] This anomalous upregulation of glycolysis despite 
aerobic conditions was thus termed Warburg effect. To counterbalance the lower ATP 
production efficiency of glycolysis, an increased glucose consumption is found in cancer cells 
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which is sustained by a higher expression of glucose transporters such as GLUT1 and thus an 
increased glucose uptake.  
Factors influencing the metabolism include HIF-1, Ras, Myc, or Akt which foster glycolysis 
with mTORC1 being a key player in induction of anabolic growth. Interestingly, also TP53 
plays a role in energy metabolism and lowers glycolysis rates while enhancing mitochondrial 
respiration. This is accomplished by running a counteractive program and lowering 
expression of glucose transporter GLUT1 and GLUT4. On the other hand, pyruvate 
conversion to Acetyl-CoA is increased and made available for mitochondrial respiration while 
being excluded as substrate for lactate production by lactate dehydrogenase. Obviously, a 
loss in TP53 reverts this glycolysis limiting steps and increases lactate production.  
1.1.2.10 Evading Immune Destruction 
Immune surveillance not just targets exogenic pathogens but also incipient cancer cells.[11] 
Deficiency in immune surveillance, such as in immunocompromised patients due to HIV 
infection or after organ transplantation, increases the cancer incidence rates strikingly.[82] 
Moreover, tumor infiltration by cytotoxic T cells is a positive prognostic factor for overall 
survival in versatile solid tumors.[83-88] Thus, they may not only be enriched in this tissue by 
chemical cues but actually play an active role in confining and eradicating tumor cells. 
This illustrates the necessity for an emerging cancer to evade recognition respectively 
destruction by immune cells. To further specify, both the innate immune system such as NK 
cells but also the adaptive immune cells such as T cells play a role in tumor eradication. This 
was supported by genetically engineered mice where a deficiency in one or the other 
facilitated the growth of tumors.[89-91] Moreover, tumor incidence could be further 
increased by a deficiency in both, T cells and NK cells demonstrating at least partial non-
redundancy and different targets for the respective immune cell arms.  
Condensing this data results in the paradigm of elimination-equilibrium-escape as three E’s 
of tumor development.[92] During elimination phase, effector immune cells such as effector 
T cells are capable of recognizing tumor antigens and eradicating the transformed cells. 
During equilibrium phase, the effector immune cells are counterbalanced by suppressive 
mechanisms such as regulatory T cells allowing the tumor lesion to persist in a confined 
environment. The escape phase is the most pathological phase where immunosuppressive 
cues outcompete the activation cues and thus abrogate the eradication of tumor cells.  
Advances in research broadened our knowledge and clearly point out the role of the 
immune system in counteracting tumor development as well as providing an outstanding 




1.2 Cancer Treatment 
1.2.1 Cancer Screening and Diagnostic 
The more specific and earlier cancer is diagnosed, the better is the outcome for a 
patient.[93] Often, early-detected, local and not-metastasized cancers can easily be resected 
with a favourable prognosis while advanced disease still imposes a poor outlook. In addition, 
regular screened patients were less likely to develop cancer and diagnosed at an earlier 
stage than unscreened patients. [94] This demonstrates the importance of screening for 
diagnosis but also the preventive effect of screenings by promoting interactions with 
medical personnel.  
Screening tests for cancer are [95]: 
1. Physical Examination and History 
 Anamnesis for drinking or smoking habits, familial medical history, etc. 
 Are lumps palpable? cachexia? visual abnormalities? (melanoma [96] or during 
colonoscopy [97]) 
2. Laboratory Tests 
 Differences in cell morphology (Pap Smear [98], skin biopsy [99])  
 Changes in marker levels in blood or urine (PSA [100], CA125[101]) 
3. Imaging procedures 
Lesions can be found by versatile methods [102, 103] such as  
 Mammography 
 X-rays 
 computer tomography (CT) scan 
 magnetic resonance imaging (MRI) scan 
 positron emission tomography (PET) scan 
 ultrasound 
Abnormal lesions usually need to be confirmed by biopsies to ensure the diagnosis. 
Imaging also helps in staging and conclusively in treatment planning. 
4. Genetic tests 
 Screening for BRCA1 and BRCA2 mutations [104] 
 Stool DNA test to screen for DNA alterations associated with colon cancer [105] 
 TP53 mutations in tubal lavage for ovarian cancer screening [106-108] 
  
Similar tests are also conducted throughout the course of disease to follow-up progression, 
therapy response or relapse.  
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While the set of screening and diagnostic tests is continuously expanding and improving, a 
lot of problems remain unresolved.[95] Screening results can be misleading, have side 
effects, be false-positive or false-negative and may not improve the person`s life expectance. 
In detail, defining the tumor marker`s cutoff level for a positive result is crucial. 
Unfortunately, deviations in protein levels may not be induced by a tumor but idiopathically 
and thus are the rule not the exception. As an example, versatile markers for ovarian cancer 
such as CA125, CA15.3, HE4 and CA72.4 were found to differ in respect of reproductive and 
lifestyle factors such as smoking.[101, 109] Non-pathological but common marker deviations 
thus impede a straightforward binary test result. 
Another example for overdiagnosis and overtreatment can be illustrate by prostate cancer 
and PSA screening. [110, 111] While PSA screening may be beneficial to preserve the 
patient’s life in cases of aggressive tumors, it may be detrimental in low-risk tumors which 
are unlikely to become life-threatening. Prostate cancer therapy such as radical 
prostatectomy or radiotherapy is associated with a variety of severe side effects such as 
urinary, sexual and bowel dysfunction.[112] In conclusion, overdiagnosis can initiate 
unnecessary treatments which drastically reduce the quality-of-live (QOL) without a 
significant clinical benefit. 
In summary, the risk for false test results can either delay therapy initiation or impose a huge 
cut in life accompanied by anxiety and emotional reactions. Thus, a close follow-up and 
interaction with experienced medical personnel is essential for cancer diagnosis and patient 
outcome to carefully evaluate the test results and decide on the most beneficial clinical 
intervention.  
Once the tumor is diagnosed, it will be staged in reference to its aggressiveness respectively 
local or distant spread. The most widely-spread staging system is the tumor, node, 
metastasis (TNM) staging system.[113] Each parameter is given a scaled number respectively 
code with higher numbers usually being less favourable. While T describes the local extend 
of the primary tumor such as size and adjacent tissue infiltration, the N describes the 
involvement and distance of the involved lymph nodes and M describes the presence and 
spreading of metastasis.  
Consecutively to cancer diagnosis and staging, the patient and involved physicians can 





Resecting the neoplastic tissue with a defined safety margin seems as straightforward 
method of choice in locally confined lesions.[114, 115] On the other hand, extensive 
operations of deep-situated tumors such as Whipple operations for pancreas tumors can go 
along with extensive side effects and limit life expectance themselves.[116] Additionally, 
sometimes tumors and the healthy margin cannot be fully resected due to involvement of 
vital structures and thus impose a risk for remaining or relapsing disease.  
While at an early stage surgery is often the only therapy, advanced disease commonly 
requires the combination with chemo- and radiotherapy. This is either done in an adjuvant 
setting by surgical tumor debulking prior to secondary therapy or a neoadjuvant setting 
where chemo- or radiotherapy is applied to reduce tumor mass prior to surgical resection.  
An example where preventive surgeries can also help to reduce cancer risk is mastectomy 
and salpingo-oophorectomy in BRCA1/2 mutation carrier or abnormal skin lesions and colon 
polyps. Moreover, surgery can also be conducted in palliative cases where it is performed to 
relieve side effects by the tumor such as bleeding or restore skeletal functions.  
Clinical outcome highly varies in dependence of tumor localization and patient 
characteristics while technological improvements such as endoscopy and the spreading of 
robot-assisted surgery helps to reduce side effects and improve the outcome 
1.2.3 Chemotherapy 
Chemotherapy describes a vast range of drugs which can be administered systemically via 
oral, intravenous or intraperitoneal administration but also topical by skin creams.[117, 118] 
In contrast to surgery, systemic chemotherapy can also target cancer cells which may not be 
reached by surgery or radiotherapy due to tumor localization. Moreover, it can also target 
small cancer lesions which may not be detected by imaging such as tissue-infiltrating cells or 
distant metastasis. 
This systemic off-site effects also describes the major disadvantage of chemotherapy and 
conclusively can cause severe side effects throughout the whole body. Due to the high 
metabolic and proliferative rate, cancer cells are most susceptible for substances interfering 
with mitosis, crosslinking DNA and preventing DNA untangling by topoisomerases. 
Unfortunately, healthy proliferative cells are also affected and displaying detrimental 
responses. This cellular response translates into versatile clinical side effects such as fatigue, 
hair loss, nausea and vomiting, mucosal inflammation, and changes in the blood count. 
Depending on severity, treatment discontinuation must be considered to limit side effects 
but also lowers tumor control.[119] Thus, the treatment response and side effects must be 
closely surveilled to allow treatment adaptation. 
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The most common types of chemotherapy used in clinics [120, 121] are: 
1. DNA-interfering agents 
 Platinum-based agents: Cisplatin/Carboplatin (crosslinking DNA) 
 Anthracyclines: Doxorubicin/Daunorubicin (DNA intercalation) 
 Mustard gas derivatives: Cyclophosphamide (DNA alkylation) 
2. Microtubule-interfering agents 
 Taxanes: Paclitaxel, Docetaxel (microtubule stabilisation) 
 Vinca alkaloids: Vincristin/Vinorelbin (microtubule destabilisation) 
3. Antimetabolites 
 Folic acid antagonist: Methotrexate 
 Pyrimidine antagonist: 5-Flourouracil, Capecitabine, Gemcitabine 
4. Topoisomerase inhibitors 
 Topoisomerase I inhibitor: Irinotecan, Topotecan 
 Topoisomerase II inhibitor: Etoposide 
5. Kinase inhibitors 
 EGFR inhibitors: Cetuximab, Erlotinib 
 VEGFR inhibitor: Bevacizumab 
(see also 1.1.2.1 Sustaining Proliferative Signaling) 
 
Mustard gas derivatives are a man-made drug, while versatile other classes of 
chemotherapeutics such as vinca alkaloids, taxanes and anthracyclines derivate from plants 
or microorganisms. Adaptations in the chemical structure helped to generate prodrugs or 
improve the pharmacological profile with higher target specificity and less off-target effects.  
Nevertheless, targeting a pristine cancer-specific proteins such as fusion protein BCR-ABL by 
Imatinib is often not possibly.[22] Therefore, advances in chemotherapeutics mainly focused 
on further improving the administration and targeting of cancer cells to reduce effects in 
healthy tissue. An example is the exploitation of leaky tumor vasculature by the enhanced 
permeability and retention (EPR) effect (as discussed in 1.1.2.5 Inducing Angiogenesis). 
Nanoparticles such as liposomes are more likely to be trapped in this vasculature and thus 
impose a promising approach to increase drug concentration in the tumor and limit it 





Due to importance and the ongoing development in clinical application, cancer-immune 
system interactions shall be further elaborated on, despite being broached above (1.1.2.10 
Evading Immune Destruction).  
More and more research data facilitates the development of novel therapies to exploit 
immune cells for therapy or prohibiting tumor cells from evading immune recognition and 
destruction.[92] To counteract and harness the immune system, understanding of the 
escape mechanisms is essential. 
The most obvious mechanism to avoid immune recognition is by downregulation of antigen 
processing respectively presentation by downregulation of MHC-I, LMP2, LMP7, or tapasin 
to avoid T cell recognition. IFN signalling on the other hand may increase the antigen 
presentation and therefore may also be negatively regulated in tumor cells. Moreover, 
cancer cells can exhaust T cells by increasing their PD-L1 and B7-1/2 presentation to PD-1 
and CTLA-4, respectively. As an example, overactivation of the proliferation-driving AKT 
pathway by PTEN deficiency could contribute to the immunosuppressive increase in PD-L1 
expression. 
Not just surface bound down or upregulations of tumor proteins but also secreted factors 
such as TGF-β, IL-8, IL-10, or VEGF dampen T cell function. Aggravatingly, these secreted 
factors also attract additional immunosuppressive cell populations such as T regulatory cells 
(Treg), myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM). 
Another immunosuppressive trait can be derived from the high metabolic turnover rate of 
tumor cells which depletes the tumor environment from oxygen, glucose, amino acids and 
lowers the pH (see also 1.1.2.9 Reprogramming Energy Metabolism) which as a result 





Figure 2 Overview of the tumor-immune cell Interface (modified from [92]) 
Tumor cells can counteract effector T cell activity by: A) reduced antigen processing/presentation, 
B) T cell exhaustion by B7-1/2 & PD-L1 upregulation, C) secretion of immunosuppressive factors 
such as TGF-β or IL-8, D) attraction of immunosuppressive cell populations such as Treg, MDSC, 
and TAM, and E) by generating an unfavourable metabolic environment 
 
Immunotherapies are changing the paradigm in cancer therapy and brought hope for 
previously only palliatively treated cancer cases. Versatile approaches such as cancer 
vaccination, modified immune cells such as chimeric antigen receptor (CAR) T cells, and 
bispecific antibodies activating T cells are currently under investigation.[123] At the present 
time, the most widely applied immunotherapy in clinics is immune checkpoint blockade 
targeting CTLA-4 and PD-1 signalling to release the brakes of effector T cells and to facilitate 
a persisting activation. While low PD-L1 expression in antigen-presenting cells (APC) is linked 
to autoimmune disease systemic lupus erythematosus[124], it is commonly overexpressed in 
tumor cells suppressing T-cell activating pathways.[125] This illustrates that this mechanism 
is clearly essential in modulating self-tolerance but can obviously be hijacked by cancer cells 









elucidation of these pathways was game changing and consequently awarded with the 
Nobel Prize in 2018. It moreover resulted in multiple clinically applied antibodies such as 
nivolumab (PD-1), pembrolizumab (PD-1), atezolizumab (PD-L1), avelumab (PD-L1), 
durvalumab (PD-L1) [126], and ipilimumab (CTLA-4)[127] which proved efficacy and are 
shifting to first-line in treatment schedule.[128-131] 
In summary, immunotherapy is a hot topic in oncology since it opened up a fully unexplored 
field in cancer therapy with versatile treatment approaches and room for advancements. 
Nonetheless, some patients are experiencing cancer cure while others are non-responding. 
Elucidating the factors involved and predicting which patients are eligible for immune 
therapy is therefore considered to be as relevant as increasing, initiating or modulating the 
immune response. Broadening our knowledge will enable to choose the right off-shelf 
therapy respectively ease the generation of personalized medicine such as (due to brevity 





1.2.5.1 History of Radiotherapy 
Radiotherapy emerged at the turn of the 20th century [132] and remains an essential therapy 
with approximately 50% of cancer patients requiring radiotherapy and increasing patient 
numbers worldwide.[133] While additional isotopes, types of radiation and treatment 
options were found and utilized without deep understanding, it was not until 1932 that 
measuring the radiation dose become possible by the first ionization chambers. The first 
cancer therapeutic approaches mainly consisted of local brachytherapy with radium and 
external X-ray beams from 50 to 200kV X-ray tubes for deep situated tumors. The 
tremendous developments in electric, electronics and computing drastically improved 
present day irradiation machines to become safer, more sophisticated in size and precision 
and more optimized in treatment planning. In addition to radioactive seeds and X-rays, also 
particle beams such as especially proton and carbon beams are currently becoming more 
powerful and convenient with center numbers increasing steadily.  
The main principle of radiotherapy is killing tumor cells and halting their reproduction which 
is consistent throughout all application methods and radiation types.[132] The most 
investigated and detrimental effect of radiation is the damaging of DNA which is expected to 
result in mutations and chromosomal aberrations which lead to arrested cell cycles, 
apoptosis, necrosis, mitotic catastrophe and ideally cancer control.[134] What makes DNA 
especially vulnerable for radiation is the huge size of the molecule offering a vast number of 
potentially broken covalent bonds. Additionally, proteins and lipids also get damaged but in 
contrast to DNA can easily by compensated for by the vast number of copies and spare 
molecules. In DNA on the other hand, there is no spare “reserve” and even a single 
unrepaired or wrongly repaired lesion could result in point mutations, deletions, insertions 
and lost or rearranged chromosomal sections and turn out as lethal for the cell.  
The following sections are intended to provide an overview of the physical principles, the 
present most common clinically applied forms of cancer radiotherapy and their respective 
basics, instrumentation and pros and cons.  
1.2.5.2 Physical basics of radiotherapy 
Depending on the transmitted energy, radiation can be ionizing or non-ionizing.[135] The 
ionizing potential for elements ranges from 3.9eV to 24.6eV for cesium and helium 
respectively and is 12.6eV for the ionization of water.[136] In dependence of type of 
radiation, ionizing radiation can be further divided in directly or indirectly ionizing radiation. 
While charged particles such as electrons, protons, alpha particles or heavy ions can directly 
interact with orbital electrons via Coulomb interactions, photons and neutrons are 
considered to ionize by a two-step process. Photons release electrons and neutrons release 
protons or heavier ions which then in turn can interact with orbital electrons in a similar 
manner as described.  
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1.2.5.3 Brachytherapy  
Brachytherapy is one of the oldest applied radiotherapies [132] and describes the treatment 
of cancer by short distance application with radionuclide sources such as 60Co, 137Cs, 192Ir, 
125I, and 103Pd.[135] These sources are mostly applied to the tumor mass intracavitarily by 
taking advantage of adjacent body cavities for short term exposure or implanted interstitially 
into the tumor for long term exposure. Typical examples are cervix cancer therapy 
respectively permanent prostate implants. The benefit of brachytherapy is the localized 
delivery of photon, beta, or neutron emitting sources to the tumor mass while limiting 
healthy tissue exposure. This advantage also describes the major drawback since only small, 
localized and well defined tumors are eligible for brachytherapy. 
1.2.5.4 External Beam - Photon therapy 
Physics and Interactions of Photons 
Photons are interacting with matter in versatile processes with some of them being 
eventually ionizing. These interactions include [135]: 
1) Photoelectric effect 
The photon interacts with a tightly bound orbital electron and disappears. The electron 
on the other hand is ejected from the atom as a photoelectron with the kinetic energy 
Ekin given as: 𝐸𝑘𝑖𝑛 = ℎ𝜈 −  𝐸𝑏𝑖𝑛𝑑𝑖𝑛𝑔 
Ekin … kinetic energy of the photo electron 
h  … Planck’s constant 
ν  … photon frequency 
Ebinding  … binding energy of the ejected electron 
2) Coherent (Rayleigh) scattering 
The photon interacts with a bound orbital electron and gets scattered by a small angle 
but does not transfer respectively lose energy.  
3) Compton effect (incoherent scattering) 
The photon interacts with an orbital electron, ejects it but does not disappear. The 
photon energy must be much larger than the binding energy, hence this effect is most 
prominent with loosely bound electrons and high-energy photons. As a result, the 
incident photon energy is shared between the kinetic energy of the ejected electron 
and the scattered photon with an accordingly lower wavelength/energy. The 
distribution of energy between photon and electron depends on the scattering angle 
of the photon and is highest for backscattered photons. 
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4) Pair production 
The photon disappears within the nuclear Coulomb field with an electron-positron pair 
being produced. The combined kinetic energy is the incident photon energy minus the 
energy required to produce the mass of an electron and a positron. 𝐸𝑘𝑖𝑛,𝑐𝑜𝑚𝑏 = ℎ𝜈 −  2 ∗ 𝑚𝑒𝑐2 
Ekin,comb … combined kinetic energy of positron and electron 
h  … Planck’s constant 
ν  … photon frequency 
me   … mass of an electron 
c  … speed of light 
Pair production is limited to photon energies above 1.02MeV which is consumed for 
producing the electron and positron (2 ∗ 𝑚𝑒𝑐2). If pair production occurs in the field of 
an orbital electron, these 3 particles share the kinetic energy. 
5) Photonuclear reactions 
High energy photons can be absorbed by the nucleus and result in the emission of a 
proton or neutron and the transmutation of the atom. This reaction requires MeV 
photon energies and is less relevant for treatment but for safety and shielding 
considerations. Produced neutrons and radioactivity impose a health risk and must be 
dealt with by improved shielding and improved room ventilation 
These discussed photon-matter interactions and their probability strongly depend on the 
photon energy and the atomic number of the irradiated matter and the respective 
probability can be seen in the following graph (see Figure 3) 
 
Figure 3 Probability of photon interactions in dependence of the atomic number of the 
target atom and the energy of the incident photon [135] 
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Direct ionizing effects in biomolecules only account for a small fraction of induced damage 
which is superimposed by the indirect effect via the generation of versatile reactive species 
from water molecules due to the vast excess of water molecules.[137] The radiolysis and 
ionization of water generates free electrons, reactive species with unpaired electrons and 
free radicals as well as recombination products such as hydrogen peroxide. This conversion 
of photon energy to chemical carriers then allows reactive species to diffuse and react with 
biomolecules in close proximity. A special focus must be drawn to the generation of 
hydrogen peroxide and hydroxyl radicals which is enhanced in dependence of elevated 
oxygen concentration within the solution. This demonstrates the importance of oxygenation 
for photon radiotherapy to increase the yield of reactive species and thus biological effect 
and is a key consideration for fractionation schemes (see also 1.3.3 Reoxygenation) 
 
 
Figure 4 Radiolysis and ionization of water and accompanying reactions [137] 
  
Clinical application, generation and instrumentation 
External beam therapy utilizes high-energy photons from nuclear reactions (gamma rays) or 
electrons interacting with a target (X-rays). Radioactive 60Co emits clearly defined photons 
with 1.17MeV and 1.33MeV but source intensity declines by time due to the radioactive 
decay. 
The energy of X-rays on the other hand can be more easily adjusted. Electrons are ejected 
from a heated filament in an evacuated tube and accelerated towards an anodic target. The 
voltage difference between filament cathode and anode describes the acceleration of the 
electrons and can easily be adjusted. These accelerated electrons are aimed at a metallic 
target where they decelerate and interact with matter. Unfortunately, most of the electrons` 
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kinetic energy is transformed to heat requiring target cooling and only a small fraction 
converted to X-ray photons.  
These incident electrons can interact with orbital electrons and eject them from their shell 
position. The filling of the vacancy by a higher level shell electron requires the filling electron 
to lose energy. This energy difference is emitted as photon and a characteristic for the target 
material.  
Bremsstrahlung on the other hand, results from interactions of the incident electrons with 
nuclei. Kinetic energy of the electron is emitted as photons during deceleration in the target 
material. Bremsstrahlung is thus material independent and provides photons in a range of 
zero up to the kinetic energy of the incident electron.  
Conclusively, the line spectrum of X-rays consists of target material specific peaks and a 
continuous broad bremsstrahlung spectra. The low energy photons in the splash of 
Bremsstrahlung are less penetrant and would cause undesirable dose deposit at the surface. 
Therefore, these low-energy photons are filtered out by thin layers of metal (such as 1mm Al 
or 0.3mm Cu) and excluded from the spectrum before the X-rays leave the beam generator. 
In addition to different filter set-ups, also the electron acceleration changes the spectrum. 
The faster the accelerated electrons are, the less pronounced are the characteristic photons 
in the total spectrum. Additionally, the average direction of photons emitted shifts from a 
90° angle at low energies (10-150kV) to a forward direction at megavoltage energies (1-
50MV) and thus also influence the construction of the X-ray source. Moreover, also the 
electron current and thus X-ray intensity can be increased by increasing the temperature of 
the filament. 
In previous times, the shape profile of the photon beam could be customized and 
personalized by often handmade metallic collimators absorbing the unwanted beam 
fraction.[138] This modulation is obviously limited to only a single angle of beam delivery 
despite tumor size being expected to change throughout treatment. A more advanced 
method are so called multi-leaf collimators where absorbing wedges can be moved in and 
out of the beam path to shape the beam profile. This also enabled more complex multi-angle 
treatment plans by rotating gantries where the beam shape must be modulated during 
irradiation. In addition to collimator improvements, also the photon sources improved 
drastically. Modern linear accelerators (LINAC) enable much higher electron velocities and 
thus photon energies which broadened the spectrum of available X-rays. Condensing all 
capabilities of modulating photon beams, resulted in the so called Intensity Modulated 
radiotherapy (IMRT) as present state-of-the-art in photon radiotherapy. For IMRT, not just 
the beam shape but also the intensity is modulated throughout an irradiation session. [139] 
Obviously, this advance in dose delivery also benefits from advances in imaging and 
sophisticated computer simulations and planning programs to optimize dose distribution 
and demonstrates the multidisciplinarity of radiotherapy 
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In summary, X-ray radiation can be adjusted more easily and is more versatile than gamma 
ray sources but requires more complex instrumentation and control units. Conclusively, 
external gamma radiation lost market shares in developed countries by the emergence of 
safer and non-radioactive linear accelerator technology. 
1.2.5.5 External Beam - Proton therapy 
Proton beam therapy was first proposed in 1946 but remained a niche treatment until 
present time.[140] Despite the recent opening of multiple proton therapy centers, the 
number of patients being treated conventionally remains more than 100-fold higher.[139]  
Proton therapy is generally more complex, more expensive and more difficult to establish 
compared to standard X-rays. Also the meter-thick concrete shielding, the beam dump and 
beam lines require space which is usually not available in historically-grown hospitals or 
adjacent city areas and conclusively prevents the integration of proton radiotherapy in 
existing facilities. As a result, most proton radiotherapy centers are located at separated 
locations with national but commonly also international patients being referred to. 
Nevertheless, current advancements in accelerator technology, a higher general interest in 
this technology and the growing market will reduce price, complexity, as well as required 
space with a so called “one-room solution” by a single provider as the final goal.[138] 
Differences in Photon and Proton Physics 
A spatially different dose distribution profile compared to photon beams make proton and 
other particles beams superior in reducing radiation damage to healthy tissue . [141-143]  
Photon beams have a lower entrance dose deposition within the first millimeters until the 
splash of ejected electrons is established and sums up with the inciding photons to the 
highest dose deposition within 2-3cm. Afterwards, the dose deposition is steadily declining 
due to absorbed photons but extends throughout the beam path. This obviously represents 
the deposition of considerable amounts of dose to superficial tissues such as skin but also 
behind the treated tumor mass. Moreover, a deep-situated tumor is expected to receive less 
dose than the entry tissue and therefore multiple angle beams must be combined to build 
up the dose in the target and dilute the dose to healthy tissue by increasing the co-irradiated 
volume.  
Protons on the other hand are following a nearly ballistic trajectory and pass through the 
tissue. The protons interact with matter, deposit their energy and decelerate. The slower the 
protons get, the more energy can be deposited per atom passed respectively distance 
travelled until they are ultimately stopped. The term describing this is the linear energy 
transfer (LET) which increases drastically towards the end of the trajectory and peaks in the 
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so called Bragg Peak where the highest dose deposition and LET is found, followed by a 
steep decline. The region of highest dose deposition can therefore be calculated and 
designed to be in the tumor by accelerating the protons to the required velocity. By 
overlaying multiple of these pristine Bragg peaks, a so called spread-out Bragg peak (SOBP) is 
generated which homogeneously covers the defined depth range with ionizing radiation. The 
deposited dose is highest in the tumor and lower in the entry tissue and conclusively reduces 
the need for multi-angle approaches. In addition, healthy tissue beyond the Bragg peak can 
be consequently spared since the protons are stopped in their trajectory. 
 
Figure 5 Dose-deposition profile of 10MV photons, pristine and SOBP protons  
(modified from [141]) 
A 10MV photon beam (A, black line) is described by a build-up in dose deposition at the entry side 
followed by a steady decline in dose deposition. A SOBP proton profile (B, red line) consists of 
multiple pristine proton beams (C, blue lines) which results in the consistent coverage of the 








Figure 6 Comparing Photon versus. Proton treatment plans (modified from [144]) 
Pencil beam scanning (A) clearly demonstrates a lower coverage of healthy tissue in a high-grade 
glioma patient than the photon beam plan (B). The difference (C) is concisely illustrated by a 
decreased dose (in blue) in most of the healthy tissue and only marginally increased dose 
depositions (in red) adjacent to the tumor volume. The dose volume histogram (D) shows the 
proportional dose deposited by the photon (dashed line) or proton treatment plan (solid line). A 
similar coverage of planning and clinical target volume (PTV and CTV) is achieved but more 
healthy tissue is receiving higher doses in the photon treatment plan.  
 
Clinical application, generation and instrumentation 
To generate and deliver protons, a complex system consisting of linear accelerator tubes, 
cyclic accelerators such as synchrotrons and cyclotrons or mixed types as well as magnetic-
focusing and beam lines is requires.  




In general, hydrogen atoms will be stripped for their electrons by thin foils and first linearly 
accelerated before being sourced into a cyclic accelerator. Cyclotrons work in a continuous 
manner, accelerating protons to a fixed velocity which can be reduced subsequently by a 
range shifter slowing protons down to the desired velocity.[138] The proton velocity can be 
more easily modulated in synchrotrons which accelerate a batch of protons to the desired 
velocity at once but work discontinuously. The ejected proton beam is guided by magnetic 
lenses through a pipe system where further controlling of beam characteristics such as beam 
current or beam profile is conducted. While only one room can be served at a time, multiple 
treatment rooms are connected to one beam line to switch between rooms where patients 
are aligned and prepared for radiotherapy. This helps to avoid unused downtimes of the 
accelerator during patient set up and alignment. Investment in additional treatment rooms 
is therefore essential to utilize most of the available beam time and exploit this usually 
limiting factor of proton therapy. 
Once the protons leave the pipe system, the beam must be shaped to cover the target 
volume. The earlier, less complex and still applied method for eye tumors is passive 
scattering. The two-dimensional beam shape is ensured by copper collimators and the beam 
axis depth profile by a compensator which protons permeate but are slowed down in a 
controlled manner. For in-treatment Bragg peak shifting, a prementioned range 
shifter/modulator is inserted into the beam. This allows to supply a Spread-out Bragg peak 
(SOBP) into the tumor without complex planning or magnetic beam modulation but 
handcrafted collimators and compensators.  
The more advanced and also for this project utilized method is pencil beam scanning (PBS) 
respectively spot scanning. Based on imaging, the tumor is dissected in layers and a 
treatment software defines single spots for each layer. The protons are directed to a spot by 
magnetic steering in the nozzle and so a defined dose applied before targeting the next spot. 
This process is repeated throughout the respective layer until all spots are scanned. By 
adjusting the velocity of ejected protons from the accelerator, the depth and thus the target 
layer in the tissue is shifted and again all calculated spots scanned. This enables to variate 
the number of spots in each layer and the location as well as the dose of each individual spot 




Figure 7 Proton beam delivery by passive scattering (A) and pencil beam scanning (B) 
(modified from [145]) 
For passive scattering (A), the focussed proton beam is scattered and shape and depth profile 
modulated by collimator and compensator, respectively. Pencil beam scanning (B) is achieved by 
steering the proton beam using magnets to pursue a programmed track. Numerous spots of 
proton splashes are administered along this track to homogeneously fill up the volume with dose. 
Both methods work by superimposing layers to generate a SOBP which is achieved by either 
inserting plates to reduce proton velocity or by a lower proton velocity supplied from the 
accelerator. 
 
1.2.5.6 Differences Photon versus Proton radiotherapy 
Despite the obvious physical differences between photon and proton radiotherapy, also the 
biological and cellular response differs.[146-149] Present treatment plans and estimations 
mostly utilize a generic relative biological effectiveness (RBE) of 1.1 as factor for dose 
calculations to account for a higher efficacy of protons compared to photons. 
This value was determined by extensive testing but probably generalizes and covers up its 
variable nature. The RBE increases along the SOBP which clearly implies a different nature 
and response to low LET photons or fast entering protons in contrast to high LET, 
decelerating, and stopping protons. The LET of carbon ions is even higher than for protons 
and so is the RBE of carbon ions.[150] Conclusively, once establishing a different biological 
response in dependence of irradiation species or a LET dependence, there is room to exploit 
it due to the widely fluctuating patient backgrounds and tumor. Shifting the paradigm to a 
biologically variable RBE also opens the door towards combinatorial approaches to target 
cellular pathways and redundancies and modulate the treatment response actively.  
Another relevant consideration in radiotherapy is the exact definition of the tumor volume 





higher doses into adjacent healthy tissue which can be avoided by proton beams and is 
therefore commonly more confined. As a result, exfiltrated tumor cells and adjacent tumor 
colonies which are not visualized by imaging are not planned into the treatment volume and 
probably not irradiated by a confined treatment plan. On the other hand, less confined 
photon treatment plans probably still deposit substantial doses of “unintended” radiation 
into these regions.  
Defining the precise tumor depth is also more relevant for finite proton beam paths than for 
less depth-restricted photon beams. Proton beams are prone to tissue movements in the 
beam axis and both overshooting into the healthy tissue as well as underdosing the distal 
tumor section a relevant issue. A way to increase robustness in pencil beam scanning is by 
reirradiation. The full tumor volume is scanned as stated in the steering file but the 
prescribed dose is split up and only a fraction applied. This allows to run multiple scanning 
rounds and reduces the risk that a piece of tissue is always out of the beam path and 
remains unirradiated. Versatile other ways of reducing tumor motion or increasing targeting 
robustness are breath holding and breath restriction by fixtures as well as live imaging of the 
patient and computer-processed counteractions by the patient bed to keep the tumor in the 
treatment field.  
More extensive and detailed reviews dealing with the differences of photon and proton 
irradiation, how to probably exploit differences in DNA repair dependency and future 
concepts can be found in 3.2 Combined Treatment Modalities for High-Energy Proton 
Irradiation: Exploiting Specific DNA Repair Dependencies [142] and 3.3 The Relative 





1.3  The 5 R`s of Radiotherapy 
1.3.1. Radiosensitivity 
Cells and tissue are described by a cell intrinsic sensitivity to radiation.[134] The extremes 
range from radiation resistant tissues and tumors such as brain tissue and sarcomas to more 
radiation sensitive tissues such as the haematopoietic system or the oral mucosa. This can 
be seen by versatile factors such as cell cycle state when being irradiated but also on a 
cellular signalling level. In general, normal cells with intermediate DNA damage can activate 
cell cycle arrest, slow down proliferation by proteins such as TP53 and conclusively buy 
sufficient time for correctly repairing the lesions. On the other hand, tumor cells are in 
general more dysfunctional and checkpoints and growth repressors incapacitated which 
results in shorter repair periods and a higher probability of prematurely proceeding in cell 
cycle and running into mitotic catastrophe. Healthy cells on the other hand are in general 
more presumable to undergo apoptosis or senescence which is less probable in tumor cells 
where these pro- and anti-apoptotic pathways are commonly dysregulated. 
This said, it becomes obvious that tissues and tumors provide different radiation sensitivities 
already upfront treatment start. 
 
1.3.2 Redistribution 
Radiosensitivity is a function of cell cycle state. The sensitivity to DNA damage increases 
from late S phase > early S phase > G1 and early G2 > late G2/M phase. Cells during S phase 
have the option to undergo error-free homologous recombination repair with DNA repair 
proteins available and DNA accessible. Late G2/M phase cells on the other hand, have 
double the DNA and thus error-sides while already having passed cell cycle checkpoints. Cells 
in early G2 may have double DNA and thus double damage sides than G1 cells, but can still 
utilize HRR. 
The significance of this differential sensitivity is that mitotic cells are more likely to be 
cleared off by radiotherapy while latent G1 or S phase cells may persist. By repetitive 
irradiations, these cells are probable to undergo redistribution and thus may become more 
radioresistant at the next treatment session. This effect of redistribution is probably more 
extensive in tumor cells with deregulated cell cycle checkpoints while healthy cells are more 
capable of arresting and persisting in less sensitive cell cycle states. Therefore, time between 
fractions becomes relevant but efforts to time it in respect of the tumor treated is made 
obsolete by the tumor heterogeneity and different growth kinetics. 
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1.3.3 Reoxygenation  
The efficacy of radiotherapy in dependence of oxygen can be clearly seen when comparing 
X-ray-irradiated oxic and hypoxic cells.[134] The sensitization by oxygen follows a sigmoidal 
response curve with the largest increase between 0.5 to 20mmHg and typical oxygen 
concentrations in venous and arterial blood ranging from 40 to 100mmHg. In conclusion, 
most normal tissue is considered well oxygenated while primitive vasculature in the high 
metabolic tumor mass results in oxygen-deprived regions. 
While the oxygenated tumor cells are expected to be killed by a considerable single dose, 
tumor cells from the hypoxic region may persist and survive. What follows is a process 
termed reoxygenation which describes the oxygenation of previously hypoxic regions due to 
less or no oxygen consumption in damaged cells respectively dead cells and increased 
oxygen diffusion distances. As a result, repetitive irradiation enables the killing of previously 
hypoxic but now reoxygenized cells in each treatment session. However, hypoxia is not a 
homogenous and predictable trait and differs between tumor entities, between patients and 
even within regions of a single tumor mass. Therefore imaging hypoxia and predicting 
treatment response is a huge challenge in todays practice 
 
Figure 8 Radiosensitizing effect of oxygen (modified from [151]) 
The radiosensitizing effect of oxygen is described by the oxygen enhancement ratio (OER) which is 
about 2.5. This implies that hypoxic cells can be considered as more radioresistant than 
oxygenated cells.  
  
Interestingly, the dependence on oxygenation status is decreasing for higher LET radiation 
such as provided by proton and carbon beams.[152-154] Nevertheless, adjusting the LET by 
LET painting and accounting for hypoxic regions is unfeasible by prementioned flaws in 















1.3.4 Repopulation  
Radiation does not differ between transformed and normal cells and thus also harm the 
healthy tissue.[134] To counteract the loss in cell number, inhabiting stem cells can initiate a 
number of processes. Tissue-homed stem cells can adapt within a week of lag time until 
increasing their proliferation to allow replacement of destroyed and damaged cells. Stem 
cells can also switch from asymmetric to symmetric divisions to regain the required stem cell 
pool. Moreover, even doomed stem cells that lost their infinite replication potential may be 
able to give rise to a finite number of offspring in so called abortive divisions as a short-term 
relieve for tissue homeostasis. These processes are termed repopulation and describe the 
mechanism in which healthy tissue can resist and adapt to radiation and endure higher total 
doses in a fractionated scheme than a single treatment. Unfortunately, tumor cells can also 
adapt to radiation by accelerated repopulation so the decision of fractionation scheme to 




Versatile cellular processes can mediate the outcome of radiotherapy. An essential task is 
the repair of induced DNA lesions by DNA repair processes.[134] As mentioned above (see at 
1.1.2.7 Genome Instability and Mutation), DNA repair is commonly abrogated in tumors. 
DNA repair deficiency can even be the tumorigenic factor for example in BRCA1/2 mutation 
carriers where homologous recombination repair (HRR) is abrogated. Obviously, these 
repair-deficient tumors will be more challenged by DNA lesions and misrepaired or missed 
out lesions become more probable than fully functional healthy cells. These tumor specific 
repair deficiencies are utilized in oncology by inhibiting repair redundancies for example by 
PARP inhibitors such as Olaparib in prementioned HRR-deficient BRCA1/2 carriers.[155] 
Due to the importance and rational of DNA repair for this project, I would like to further 
elaborate on this topic and provide more details. The most commonly induced lesions by 
radiotherapy are DNA base damage, abasic sites, and DNA single strand breaks while DNA 
double-strand breaks and complex DNA damage consisting of multiple lesions within close 
proximity only accounts for a minor fraction. The following table provides an overview of 






Table 2 Overview of DNA lesions induced by ionizing irradiation (modified from [156]) 
 
Lesion No./Gy/cell Repair machinery Sensing/signalling proteins 
Base damage 1000 Base-excision repair (BER) DNA glycosylases [157] 
Single-strand 
break (SSB) 




A) Non-homologous end joining 
(NHEJ, all cell cycle phases) 
B) Homologous recombination repair 
(HRR, S & G2 phase) 
1) MRN→ATM→γH2AX 
2) Ku→DNA-PKcs→γH2AX 
3) ATR→γH2AX [134] 
 
Despite their lower occurrence, DNA DSBs are considered as most lethal and most 
detrimental lesion. Therefore, BER and SSBR which are relevant for repair of ionizing-
radiation-induced DNA lesions are not further elaborated on as well as mismatch repair 
(MMR) and nucleotide excision repair (NER). Conclusively, I want to draw your attention to 
non-homologous end-joining (NHEJ) and homologous recombination repair (HRR) which are 







NHEJ is a relatively fast and straightforward process and accounts for the majority of 
repaired DNA DSBs.[159] NHEJ is not limited to a specific cell phase and is initiated by the 
binding of a Ku70/80 heterodimer to both free ends.[160] The high abundance of Ku with 
about 400.000 molecules per cell accounts for it as being considered the first protein binding 
and stabilizing the broken DNA ends. The Ku heterodimer can be further considered as tool 
belt for the recruitment of DNA-PKcs and other processing enzymes. Trimming can be 
required and accomplished by nucleases such as Artemis or gaps filled by DNA polymerases 
(Polμ or Polλ). A complex of LIG4, XRCC4, and XLF then finalizes the repair by ligating the 
ends. Terminal microhomologies can simplify processing during NHEJ and already a 4-
nucleotide overhang is sufficient for religation by only the XRCC4/LIG4 complex. 
End processing by nucleases and polymerases imposes a risk for the introduction of errors 
respectively a recombination of different ends than intended. The risk of chromosomal 
rearrangements or mutations must therefore be considered but is overweight by the benefit 
of a fast repair.  
 
1.3.5.2 HRR 
HRR requires more processing in comparison to NHEJ and is limited to S and G2 phase where 
sister chromatids are present.[159] Whereas HRR can result in loss of heterozygosity, it is 
less prone to errors since a template is used for end processing and strand replication. HRR 
is irreversibly initiated by the exonucleolytic 5’-3’ resection of the DNA ends and facilitated 
by the MRN complex and CtIP. The generated single-stranded overhang is initially coated 
with RPA which gets replaced by RAD51 by the action of BRCA2. The nucleoprotein filament 
is then capable of invading the sister chromatid and searching for sequence homologies. 
Once the strands are aligned, the undamaged strand is utilized as a template for strand 
extension beyond the previous DSB site. This restores any lost sequence before the complex 
DNA structure involving two Holliday junctions is resolved by different complexes involving 
proteins such as BLM, GEN1, MUS81, or SLX4.[161, 162] 
Despite the benefit of theoretical error-free repair, a tight regulation of HRR is essential 
since end resection in not yet copied DNA regions during S phase and uncontrolled end 





Figure 9 Schematic overview of NHEJ and HRR (modified from [159]) 
1.3.5.3 Pathway choices during DNA DSB repair 
The main cues for pathway choice is by cell cycle and can be illustrated by CtIP. End 
resection requires CtIP phosphorylation which is achieved by S/G2-specific cyclin-dependent 
kinases (CDKs). Moreover, CtIP is proteasomally degraded during G1 phase and end 
resection therefore prevented. Also NBS1, part of the MRN complex, is phosphorylated by 
CDK1 during S, G2 and M phase adding another layer of regulation. Moreover, structural 
proteins such as cohesion, condensin and SMC5/6 are utilized to confine HRR to already 
replicated stretches of DNA. 
The fluctuations of DSB repair choice become self-evident at the example of 53BP1 and 
BRCA1.[164, 165] 53BP1, a protein associated with foci of DNA repair, prevents DNA end 
resection, therefore promotes NHEJ and is counteracted by BRCA1. Mutations in BRCA1 
occurring spontaneously or inherited, thus limit DSB repair to NHEJ. This can be exploited by 
inhibition of PARP1 which is essential in marking single-strand breaks which therefore 
remain unrecognized. When an unrepaired SSB is channeled into a replication fork during S 
phase, it generates the complex situation of a dsDNA with a SSB and another strand with a 
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free double-stranded end triggering DNA DSB repair. Realignment with the corresponding 
homologous site and restarting the fork requires a functional HRR machinery and cannot 
satisfyingly be replaced by NHEJ. This repair deficiency underlies the sensitivity of HRR-
deficient cells for PARP1 inhibitors such as Olaparib.[155] To close the circle, a secondary 
mutation disabling 53BP1 in these cancer cells relieves the breaks on end resection and 
restores HRR capacity. 53BP1 mutation is therefore a considerable mechanism for 
chemoresistance in BRCA1-deficient cancer cells by shifting the DSB repair pathway choice. 
Obviously, versatile other repair processes, examples and repair proteins would be worth 
nodding but would go beyond the scope of this thesis.  
1.4 Difficulties of cancer therapy and overcoming approaches 
1.4.1 What is the tumor? 
Cancer describes not a single pathogen causing a specific symptom but describes the 
uncontrolled growth of patient-originating cells. As versatile as the patients are the tumors 
emerging and even within a single tumor mass, a huge variability of cancer cells is evident. 
The breathtaking advances in Next-Generation Sequencing (NGS) and computational power 
of systems biology provide the scientific community with new insights on tumor 
heterogeneity.[166, 167] Previously, oncologists were able to determine the originating 
tissue, the histologic morphology and maybe a handful of tumor mutations or driving events. 
Today, cancer biologists got the tools to define subsets of subsets of cancer cells, to simulate 
evolution within a tumor and sometimes even predict upcoming therapy resistances.  
This already points out to the essential problem of cancer therapy. In most cases, not a 
single clone of similar cells is being treated but an army of cells harnessed with more or less 
resistance mechanisms, being nutrient-deprived or highly metabolic, undergoing fast cell 
cycle alternations or being dormant for month. The harsh and hostile environment for 
cancer cells results in selection pressure where evolution steps in and diverse clones then 
outcompete others for faster growth or less immunogenicity. Aggravatingly, it is commonly 
not the primary tumor being lethal but the aggressive offspring and metastasis interfering 
with the delicate balance of life. What must also be considered is that administering anti-
tumor therapy may reduce tumor mass but could also raise the selection pressure and 
promote the emergency of more aggressive clones. 
Exploiting the more adaptable immune cells by cancer immunotherapy added a novel tool 
but also proton radiotherapy may provide clinicians with a new flavor of therapy. The slightly 
different response to protons than compared with conventional photons could become 
important in certain tumor cases or when combined with certain therapies.  
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It is therefore evident that further research is required to elucidate the features and clonal 
origins of cells, to understand what therapy is most helpful for a specific tumor and what 
combinations should be administered to block resistances beforehand and stay ahead of 
tumor evolution.  
1.4.2 Normal tissue toxicity 
Next to understanding the tumor, it is also pivotal to reduce side effects in normal tissue. 
Severe side effects can drastically reduce quality of life (QOL) and turn cancer therapy into a 
disadvantageous and harming treatment. Moreover, side effects not just reduce QOL as one 
of the most important patient read outs but also compromise treatment efficacy by forcing 
treatment interruptions or terminations. Needless to say, this not just provides healthy cells 
with time for recovery but also tumor cells. Thus, all treatment options must be weigh 
before decisions are taken with a huge demand for improved and novel therapies to reduce 
normal tissue toxicity.  
An obvious improvement in radiotherapy could be provided by particle beams limiting co-
irradiation of healthy tissue. Proton radiotherapy reduces the whole-body dose [168-170] 
and current data suggests reduced side effects but clear clinical data is just being 
produced.[171-173] Thus, a more widespread application of particle beam therapy can be 
predicted but treatment slots and centers must be expected to remain the limiting factor.  
1.4.3 Where is the tumor located? 
The most evident factor and currently also main decision factor for proton radiotherapy is 
the location of the tumor. A variety of organs at risk (OAR) such as brainstem, oral mucosa, 
or the heart are known to be sensitive to radiotherapy and should be spared from 
irradiation. Tumors adjacent or in front of OAR thus impose an imminent threat and co-
irradiation becomes an unavoidable trade off to tumor control. The more widespread 
application of particle beams on the other hand provides radiation oncologist with a 
versatile tool to deliver a homogeneous dose into the tumor volume despite sparing OARs.  
The patient population most prone for late side effects after radiotherapy are paediatric 
patients.[174, 175] This is on the one hand reasoned by their long life expectance 
subsequent to therapy but on the other hand by their smaller body size narrowing down the 
safety margins and increasing the proportion of co-irradiated tissue compared to an adult. In 
conclusion, paediatric cancer patients clearly benefit from proton radiotherapy. 
In summary, proton radiotherapy could ascend from a niche treatment to a key player in 
cancer therapy. Advances in accelerator technology lowering the price are expected to 
increase access to this therapy and remove economic barriers. In addition, obvious physical 
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benefits in superior dose distribution and healthy tissue sparing support the more extensive 
prescription of proton radiotherapy. In contrast to the confirmed physical benefits, there is 
an urgent demand for further research to elucidate the radiobiological aspects of proton 
radiotherapy and the widely unestablished factors triggering the prementioned differential 




2. Aims of the study 
Proton treatment provides a superior dose distribution profile but remains a niche 
treatment in comparison to photon radiotherapy with less than 1% of patients receiving 
protons. Despite the financial burden, huge efforts are taken worldwide to increase the 
numbers of treatment facilities and improve patient access. This increase is furthermore 
expected to be facilitated by advances in accelerator and beam line instrumentation which 
lower financial and spatial requirements of new facilities and conclusively promote 
availability to the public. 
Nevertheless, the differential biological processes subsequent to irradiation with proton 
beams remain a black box for radiation oncologists. A different type of physical induction 
implies a strong rational for a different type of biological response which in turn implies a 
chance for clinical exploitation.  
This PhD project therefore aims to shed light on proton radiobiology, cellular responses and 
in particular DNA DSB repair to ultimately provide a rational for novel radio-
chemotherapeutic approaches. Thus, our specific aim was to further specify the role of HRR 
in response to proton radiotherapy and the rational-driven selection of a promising small-
molecule inhibitor in consideration of a potential future clinical application. Versatile 
methods were utilized to broaden our current knowledge and reveal the underlying 
mechanism of differential response to photon respectively proton radiotherapy.  
Our specific aims is the investigation of small-molecule inhibitors with a rational to suppress 
HRR and are thus hypothesized to more extensively sensitize for SOBP proton than for 
conventional photon irradiation. A549, H1299, FaDu, and HeLa cells are combined with 
either Ganetespib, Gemcitabine, or Triapine at varying doses and photon irradiation to 
define the respective sublethal dose range by proliferation assay and clonogenic cell survival 
assay. Due to beam time limitations, only A549 and FaDu cells and only Ganetespib are 
further investigated in combination with proton irradiation of a lower (2.1keV/μm) and a 
higher (4.5keV/μm) LET. This resembles a SOBP as clinically administered to the gross tumor 
volume. The influence of Ganetespib and irradiation on Rad51 protein levels, cell cycle 
distribution and DNA repair are investigated by Western Blotting, flow cytometry and 
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Figure 1 Clonogenic cell survival of A549  
Clonogenic cell survival of A549 cells treated with and without Ganetespib (2nM) and 200kV 
reference photon or proton irradiation at the proximal (A) or distal (B) position of a SOBP with LETs 
of 2.1 and 4.5keV/μm, respectively. The relative biological effectiveness (RBE) at (C) 50%, (D) 25%, 
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Figure 2 Clonogenic cell survival of FaDu  
Clonogenic cell survival of FaDu cells treated with and without Ganetespib (1nM) and 200kV 
reference photon or proton irradiation at the proximal (A) or distal (B) position of a SOBP with LETs 
of 2.1 and 4.5keV/μm, respectively. The relative biological effectiveness (RBE) at (C) 50%, (D) 25%, 




Deycmar et al., 2020 
HSP90i by Ganetespib selectively radiosensitizes cancer cells 




Figure 3 Cell cycle analysis of A549 
A549 cells received 4 Gy of the respective irradiation and were analyzed at (A) 0h, (B) 8h, (C) 24h, and 
(D) 48h after irradiation. Cell cycle phases were gated in single cells by DNA content and BrdU 
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Figure 4 Western Blot analysis of A549  
Analysis of Rad51 protein levels in response to photon, proximal SOBP proton or distal SOBP proton 
irradiation. A549 cells were harvested (A) 8h, (B) 24h, and (C) 48h subsequent to 4Gy of the indicated 
type of irradiation and analyzed by immunoblotting. The first lane (ctrl, 0), which represents an 
unirradiated, untreated control lysate, was utilized for normalizing protein levels in between the 
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for proximal and distal Spread-Out Bragg peak (SOBP) proton irradiation 
 
 
Figure 5 Nuclear γH2AX foci analysis of A549  
A549 cells were fixated 0.5h and 24h subsequent to irradiation with 2Gy (A) photons, (B) proximal 
SOBP, or (C) distal SOBP protons. Nuclear γH2AX foci were stained with fluorophore-labelled 
antibody and DAPI as nuclear counterstain. Cells were investigated by immunofluorescence 
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Tab. E1 Clonogenic cell survival RBEs and DMFs of A549  
A549 cells were pretreated 1hr prior to irradiation with 2nM Ganetespib or sham treatment. 
Subsequent to irradiation, a defined numbers of cells were plated in Ganetespib or sham-treated 
medium as described in Methods E4. Three independent clonogenic assay sets were generated and 
utilized to calculate the DMFs and RBEs at 50%, 25% and 10% cell survival, respectively. 





proximal SOBP, 2nM 1.337 0.098 
distal SOBP, sham 0.921 0.108 
0.0176 
distal SOBP, 2nM 1.325 0.099 
 





proximal SOBP, 2nM 1.269 0.067 
distal SOBP, sham 1.014 0.049 
0.0110 
distal SOBP, 2nM 1.285 0.067 
 





proximal SOBP, 2nM 1.218 0.045 
distal SOBP, sham 1.112 0.039 
0.0235 
distal SOBP, 2nM 1.254 0.042 
 
DMF50 mean stdev p value* 
photon 0.9183 0.050  
proximal SOBP 1.322 0.048 0.0021 
distal SOBP 1.327 0.123 0.0031 
 
DMF25 mean stdev p value* 
photon 0.9667 0.024  
proximal SOBP 1.234 0.027 0.0010 
distal SOBP 1.226 0.061 0.0205 
 
DMF10 mean stdev p value* 
photon 1.021 0.015  
proximal SOBP 1.164 0.014 0.0011 
distal SOBP 1.151 0.020 0.0028 
 





Fig. E1  Clonogenic cell survival - DMFs of A549  
Fig. E1. Clonogenic cell survival of A549 cells treated with and without Ganetespib (2nM) and (A) 
200kV reference photon or proton irradiation at the (B) proximal or (C) distal position of a SOBP with 
LETs of 2.1 and 4.5keV/μm, respectively. The sensitizing effect of Ganetespib was determined by the 





Tab. E2 Clonogenic cell survival RBEs and DMFs of FaDu 
FaDu cells were pretreated 1hr prior to irradiation with 1nM Ganetespib or sham treatment. 
Subsequent to irradiation, a defined numbers of cells were plated in Ganetespib or sham-treated 
medium as described in Methods E4. Three independent clonogenic assay sets were generated and 
utilized to calculate the DMFs and RBEs at 50%, 25% and 10% cell survival, respectively. 
DMF50 mean stdev p value* 
photon 1.058 0.021  
proximal SOBP 1.249 0.037 0.0044 
distal SOBP 1.345 0.055 0.0139 
 
DMF25 mean stdev p value* 
photon 0.997 0.010  
proximal SOBP 1.165 0.010 0.0003 
distal SOBP 1.190 0.002 0.0010 
 
DMF10 mean stdev p value* 
photon 0.960 0.008  
proximal SOBP 1.088 0.010 0.0004 
distal SOBP 1.089 0.035 0.0248 
 
*Compared to photon, two-tailed T test 
 





proximal SOBP, 1nM 1.293 0.035 
distal SOBP, sham 1.321 0.042 
0.0233 
distal SOBP, 1nM 1.679 0.087 
 





proximal SOBP, 1nM 1.358 0.027 
distal SOBP, sham 1.334 0.029 
0.0017 
distal SOBP, 1nM 1.592 0.030 
 





proximal SOBP, 1nM 1.381 0.020 
distal SOBP, sham 1.344 0.070 
0.0544 





Fig. E2  Clonogenic cell survival - DMFs of FaDu 
Fig. E2. Clonogenic cell survival of FaDu cells treated with and without Ganetespib (1nM) and (A) 
200kV reference photon or proton irradiation at the (B) proximal or (C) distal position of a SOBP with 
LETs of 2.1 and 4.5keV/μm, respectively. The sensitizing effect of Ganetespib was determined by the 







Methods E1. Cell culture conditions and Ganetespib treatment 
A549 and FaDu cells were cultured in RPMI 1640 containing 2mM L-glutamine, 10% FBS, 
1mM sodium pyruvate, 25mM HEPES and 100U/ml penicillin, 100µg/ml streptomycin, and 
0.25µg/ml amphotericin B. All cells were maintained at 37°C in a humidified atmosphere 
with 5% CO2. Prior to reaching confluency, cells were detached with trypsin-EDTA (0.05%) 
and subcultured in T25 and T75 cell culture flasks. Cells were regularly tested mycoplasma-
free by a commercial kit (Lonza, MycoAlert) and during microscopy with DAPI (5μg/ml in 
PBS) as DNA-intercalating dye.  
For drug treatment, Ganetespib was dissolved and diluted in DMSO to achieve a stock 
concentration of 10μM and stored at -20°C. For treatment, fresh supplemented medium was 
mixed with Ganetespib to achieve the defined concentration and used to replace the 
previous growth medium approximately 1 hour before irradiation. For sham treatment, the 
same amount of DMSO was added to the medium and exchanged similarly to exclude effects 
by DMSO itself. Cells were retained in drug/sham-containing medium until 
fixation/harvesting.  
For experiments, exponentially growing cells were seeded in 9cm² slide flasks at a cell 
density of 5.000 to 15.000 cells/cm2 and at least 36h prior to irradiation to allow cell cycle 
redistribution. For horizontal irradiation, the flasks had to be turned upwards and were 
consequently filled air-bubble free with the respective cell culture medium. This is essential 
to eliminate undesirable proton beam inaccuracies. After irradiation, the medium was 
completely removed and replaced with fresh drug/DMSO-containing medium to restore gas 
exchange. 
Methods E2. Photon irradiation 
For reference irradiation, 200kV photons were administered using a horizontal irradiation 
cabinet (YXLON, TU32-D03, 20mA, 5.5FOC, filtration: 3mm Be + 3mm Al + 0.5mm Cu). Slide 
flasks where positioned at 40cm distance from the beam exit window in a PMMA holder to 
provide a homogeneous distribution and a dose rate of 1.28Gy/min. 
Methods E3. Proton irradiation 
Slide flasks were submerged in a water/PMMA phantom at a proximal (55mm depth, LET 
2.1keV/µm) and a distal position (105mm depth, LET 4.5keV/µm) of a SOBP. The SOBP 
ranged from 40 to 120mm depth which correlates to proton beam energies ranging from 
66.5MeV to 136MeV. The submersion in water is essential to avoid uncertainties and mimic 
beam alterations by the aqueous environment in human tissue. Dose-averaged LETs are 
obtained from Monte Carlo simulations by the treatment planning software (RayStation). 
Protons were administered by spot scanning with dosimetric characterization and treatment 




Clausen, M., et al. (2019). "Phantom design and dosimetric characterization for multiple simultaneous cell 
irradiations with active pencil beam scanning." Radiat Environ Biophys 58(4): 563-573. 
Fig. E3. Proton irradiation: instrumentation, phantom, and set-up 
Fig. E3 (A) Fixed horizontal proton beam line. The phantom is placed on the robotic patent stage as 
marked with a red box. Beam direction is marked by a bright yellow arrow. (B) CT image (top view) of 
the PMMA/water phantom. The blue box illustrates the planned treatment field and the blue lines 
the position of the cell layers in the treatment field as indicated by red arrows. (C) Dose/LET 
simulation of the administered SOBP. The respective depths of the cell layers in the SOBP are 
indicated by red arrows and the corresponding dose-averaged LET illustrated by dashed line. (D) 
Accurate and reproducible alignment of the PMMA/water phantom was assured by positioning lasers 
in the treatment room.  
 
Methods E4. Clonogenic cell survival assay 
Exponentially growing cells were seeded and drug-treated as described above. Samples 
received an irradiation dose of 2Gy, 4Gy, and 6Gy, respectively. Reference non-irradiated 
samples (0Gy) were treated similarly and placed in the treatment room but not the beam 
line for a comparable time.  
Subsequent to irradiation, the cells were detached from the slide flasks, counted, diluted 
accordingly and plated into 6-well plates in sextuplicate to achieve approximately 20 to 300 
clones per well. After 7 (A549) respectively 14 days (FaDu), the cells were washed with PBS, 
fixed with MeOH:HAc (3:1), air-dried and subsequently stained with crystal violet (2%). 
Counting was performed manually in a blinded fashion and clones above 50 cells considered 




The plating efficiency was derived from unirradiated samples and considered when 
calculating the fraction of surviving clones. The clonogenic assays were conducted in 
triplicate and a linear-quadratic model applied to allow calculation of DMF and RBE value 
according to following equations: 
Linear-quadratic model: 
  y=exp(-(α*x + β * x^2)  
y surviving fraction 
x dose [Gray] 
weighted by 1/y2 (minimizing relative squares) 
 
Relative biological effectiveness: 
 RBEy =   dosey survival, photon, sham  / dosey survival, proton, sham  
respectively  dosey survival, photon, Ganetespib-treated  / dosey survival, proton, Ganetespib-treated   
 
Dose-modifying factor: 
  DMFy =   dosey survival, sham / dosey survival, Ganetespib-treated 
 
The dose to achieve 50%, 25%, and 10% survival rate corresponds to radiation doses 
administered by hypo- and regular fractionation schemes 
For statistical analysis, DMF and RBE values were plotted in GraphPad Prism (Version 5.03) 




Methods E5. Flow Cytometry – Cell cycle distribution  
Cells were seeded, treated and irradiated with a dose of 4Gy as described above. Cells were 
harvested at 0h, 8h, 24h, and 48h to investigate the initial cell cycle distribution as well as 
irradiation-induced cell cycle alterations. Consequently, medium was replaced with BrdU-
containing (10µM) medium 1hr before fixation to label DNA-polymerizing cells . At the 
respective time points, cells were trypsinised, washed with PBS, resuspended in 100μl PBS 
and fixated by addition of 1ml ice-cold EtOH (80%) while vortexing. Fixed cells were stored at 
-20°C until staining took place. 
For staining, cells were washed with PBS, treated with 4M HCl (10min) to denature DNA, 
neutralized with PBS, incubated in blocking buffer (1hr, room temperature) and 
subsequently in staining solution (1.5hrs, dark, room temperature). Stained cells were 
washed with PBS, filtered through a cell strainer prior to flow cytometry (FACSCanto II, BD 
Biosciences) and the obtained data analyzed with FlowJo (Version 10.5.2). 
For cell cycle analysis, a duplicate of A549 samples was seeded, irradiated, and stained 
independently. A third iteration could not be obtained due to strict limitations in proton 
beam time.  
Hierarchy - Cell cycle distribution PI content BrdU 
Single cells (FSC-H/FSC-
A) 
   
→ G1 phase 2N negative 
→ S & early G2 phase between 2N to 4N positive 
→ Late G2 & M phase 4N negative 
 
 
 Compound concentration notes 
Blocking Buffer BSA 0.5% In 1xPBS 
 Tween 20 0.1% 
 RNase A solution 0.5% 
 
 Compound concentration notes 
Staining solution antiBrdU-FITC 5μg/ml in blocking buffer 
 Propidium iodide 5μg/ml 





Methods E6. Western Blotting 
A549 cells were handled similarly to the flow cytometry samples and seeded, treated, and 
irradiated with a dose of 4Gy as described above. Upon harvest at 8h, 24h, and 48h post-
irradiation, cells were washed with PBS, lysis buffer added and distributed homogenously by 
a cell scraper. The obtained lysates were heated for 95°C (10min) and stored at -20°C. Due to 
similar cell numbers seeded and low protein concentrations as determined in pilot 
experiments, no dilution step was performed. 
For SDS-PAGE, a separation gel (10% acrylamide, 1.5mm thick) with stacking gel on top was 
self-cast and a gel electrophoresis system utilized. Samples were mixed with 5x sample 
buffer (containing 10% freshly added 2-mercaptoethanol) and 30 μl of this mixture loaded 
per gel slot.  
The proteins were electrophoretically separated (80V until front reaches separation gel, 
100V until front reaches end of separation gel), blotted onto a PVDF membrane (70min, 
80V), the membrane blocked for 1hr with blocking buffer and incubated overnight at 4°C 
with primary antibody diluted in blocking buffer. Membranes were washed three times for 
10min each with TBS-T, incubated with secondary HRP-labelled antibody (1hr, room 
temperature) and subsequently washed again as described. Protein detection was 
accomplished by overlaying the membrane with HRP substrate and the resulting 
chemiluminescence imaged with a photo cabinet. Protein quantification of the respective 
bands was enabled by Fiji (Version 1.52g) and results normalized to the β-actin loading 
control as well as an untreated control sample which was included in each run in the first 
lane. This enables comparison of protein levels also in between membranes. 
 
Reference 
Schindelin, J., et al. (2012). "Fiji: an open-source platform for biological-image analysis." Nat Methods 9(7): 676-
682. 
 
Buffer & PAGE gel compositions 
 compound concentration notes 
Lysis Buffer Tris 50mM Adjust pH to 6.8 
 SDS 2% 
 Glycerin 10% 
 
 compound concentration notes 
5x Loading Buffer Tris 125mM In deionized water 
pH 6.8  SDS 5% 
 Glycerin 25% 
 Bromophenol blue 0.25% 
 2-Mercaptoethanol 10% added right before mixing with 
samples 
 
 compound concentration notes 




 compound concentration notes 
Running Gel Buffer Tris 182g/l (1.5M) Adjust pH to 8.8 
 SDS 1g/l (0.1%) 
 
 compound concentration notes 
Stacking Gel Buffer Tris 60g/l (0.5M) Adjust pH to 6.8 
 SDS 1g/l (0.1%) 
 
 compound concentration notes 
Running Buffer (10x) Tris 30g/l dissolved in 1l deionized water 
and diluted accordingly  Glycine 144g/l 
 SDS 10g/l 
 
 compound concentration notes 
Blotting Buffer (10x) Tris 60g dissolved in 1l deionized water 
and diluted accordingly  Glycine 144g 
 SDS 2g 
 Methanol 20% Added upon dilution 
 
 




Running Gel deionized water 6.25ml  
 Running Gel Buffer (pH 8.8) 3.75ml  
 Acrylamide (30%) 5ml 10% 
 TEMED 8.5μl  
 APS (10%) 85μl  
 overlay with 2-propanol and allow time for polymerization 
    
    
Stacking gel deionized water 4.27ml  
 Stacking Gel Buffer (pH 6.8) 1.75ml  
 Acrylamide (30%) 0.91ml 3.9% 
 TEMED 7μl  
 APS (10%) 35μl  
 insert sample comb (10wells) and allow time for polymerization 
 
 compound concentration notes 
TBS-T (10x) NaCl 80g/l dissolved in 1l deionized water 
and adjust pH to 7.4  KCl 2g/l 
 Tris 30g/L 
 Tween 20 0.1% Added upon dilution 
 
 compound concentration notes 





Methods E7. Immunofluorescent nuclear γH2AX foci staining 
A549 cells were seeded, treated and irradiated with a dose of 2Gy as described above. Cells 
were fixed 0.5h and 24h subsequent to irradiation with formaldehyde-based fixative (4%. 
15min, 4°C) and slide flasks filled up with PBS for transport and storage at 4°C.  
For staining, the upper chamber part was carefully removed and the fixed cells on the plastic 
microscopy slide made accessible for following staining steps. Homogenous antibody and 
dye distribution was assured by careful overlay with parafilm. Cells were incubated with 
blocking buffer (1hr, room temperature) followed by staining solution (overnight, 4°C, dark) 
and washed three times with blocking buffer. Slides were subsequently stained with DAPI 
(30min, room temperature, dark) before washing three times in PBS. Anti-fade mounting 
medium and a cover slip were subsequently overlayed and the edges sealed with nail polish 
for storage at 4°C in the dark. 
Microscopy was accomplished by utilizing an immunofluorescence microscope (Leica 
Thunder). Foci numbers were assessed by applying the “find maxima”-function of open 
source Fiji (Version 1.52g) and the data plotted in GraphPad Prism (Version 5.03). 
 
 Compound concentration notes 
Blocking Buffer FCS 10% in 1x PBS 
 Triton X-100 0.2% 
 
 Compound concentration notes 
Staining solution anti – γH2AX-AF647 1:50 
(no absolute conc. 
retrievable) 
in blocking buffer 
 
 Compound concentration notes 
DAPI solution DAPI 5μg/ml In 1x PBS 
 
Reference 





Methods E8 Lists of Reagents, Antibodies & Dyes, and Instruments 
Reagents and consumables 
Reagent Manufacturer/supplier Order code Described in 
Nunc™ Lab-Tek™ Flask on Slide ThermoFisher Scientific 170920 E1 
Ganetespib Selleckchem S1159 E1 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich D8418-500ML E1 
RPMI-1640 (+ 2mM L-Glutamine) Gibco 11875-085 E1 
HEPES (1M, 40x) Gibco 15630-080 E1 
Sodium pyruvate (100mM, 100x) Gibco 11360-039 E1 
FBS, heat inactivated Gibco 10500-064 E1 
0.05% Trypsin-EDTA (1x) Gibco 25300-054 E1 
Anti-Anti (100x) Antibiotic-Antimycotic Gibco 15240-062 E1 
PBS (1x, Dulbecco`s Phosphate Buffered Saline) Gibco 14190-094 E1 
MycoAlertTM mycoplasma detection kit Lonza LT03-318 E1 
Methanol 99% Thommen-Furler AG 203-Cl03K E4, E6 
Acetic acid (glacial) Merch KGaA 1.00063.1000 E4 
Crystal violet Sigma-Aldrich C6158-100G E4 
Ethanol (absolute) Honeywell 10311036 E5 
Hydrochloric acid (32%) Merck KGaA 1.00319.1000 E5 
Bovine Serum Albumin Sigma-Aldrich A9647-500G E5 
5ml polystyrene round-bottom tube with cell-
strainer cap 
Falcon 352235 E5 
RNase A Solution Sigma-Aldrich R6148-25ML E5 
10% SDS solution Applichem 146132.1315 E6 
Trizma base (Tris) Sigma-Aldrich 93352-1KG E6 
Acrylamide BioAcryl-P (30%, 37.5:1) AlfaAesar J61505 E6 
TEMED Bio Rad 1610800 E6 
Ammonium Persulfate (APS) Bio Rad 1610700 E6 
2-Mercaptoethanol Sigma-Aldrich M3148-250ML E6 
Glycerin Fluka 49767 E6 
Glycine Sigma-Aldrich G7126-1KG E6 
Cell scraper TPP 99002 E6 
Sodium chloride (NaCl( Sigma-Aldrich 71380-1KG E6 
Potassium chloride (KCl) Sigma-Aldrich P9541-500G E6 
TWEEN 20 Sigma-Aldrich P2287-100ML E6 
Western blotting membrane, PVDF, Hybond P, 
pore size 0.45μm 
GE Healthcare 10600023 E6 
Blotting-Grade Blocker – non-fat dry milk Bio Rad 1706404 E6 
ECLTM Prime Western Blotting Detection 
Reagents 
GE Healthcare RPN2232 E6 
2-Propanol Sigma-Aldrich I9516-500ML E6 
Full Range RainbowTM Recombinant Protein 
Molecular Weight Marker 
GE Healthcare RPN800E E6 
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ROTI HistoFix 4% Roth AG P087.5 E7 
Laboratory Film, Parafilm Sigma-Aldrich P6543-1EA E7 
Triton X-100 Sigma-Aldrich T8787-100ML E7 
ProLong Gold Antifade reagent Invitrogen P36930 E7 
 
Antibodies and dyes 
Reagent Species stains… Concentration 
applied 
Supplier Order code Method 
5-Bromo-2’-deoxyuridine (BrdU)  incorporated into 
polymerizing DNA 
10μM Sigma-Aldrich B5002-5G E5 
anti-BrdU-FITC mouse BrdU 5μg/ml Roche 11202693001 E5 
Propidium iodide  DNA 5μg/ ml Fluka 81845-100MG E5 
anti-Rabbit-IgG-HRP mouse rabbit IgG 1:3000 Santa Cruz 
Biotechnology 
sc-2357 E6 
anti-mouse-IgG-HRP sheep mouse IgG 1:3000 GE Healthcare NA931V E6 
anti-Rad51 rabbit Rad51 1:1000 BioAcademia 70-002 E6 
anti-β-actin mouse β-actin (loading control) 1:4000 Sigma-Aldrich A5441-.2ML E6 
4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) 
 DNA 5μg/ml Sigma-Aldrich D9542-10MG E7 
anti H2AX(pS139)-AF647 mouse H2AX(pS139) 1:50 BD Pharmingen 560447 E7 
 
Instruments 
Name Supplier Method 
Vi-Cell XR (cell counter) Beckman Coulter Life Sciences E4 
FACSCanto II (flow cytometer) BD Biosciences E5 
FUSION FX7 edge (Photo cabinet) Vilber E6 
Mini-PROTEAN TetraCell BioRad E6 
Mini-PROTEAN TetraCell Casting Module BioRad E6 
PowerPac HC (power Supply) BioRad E6 
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4.1 Current Proton Radiotherapy 
Proton therapy is an outstanding method and bears the potential to supplement or even 
substitute photon irradiation in certain clinical situations. The demand for a more confined 
treatment which limits damage to healthy tissue and maximizes tumor control is imminent 
and supports a wide spread application of proton radiotherapy despite the financial burden. 
Nowadays, proton treatment plans are frequently superior as illustrated by a reduced dose 
to healthy tissue and the specific sparring of critical structures. Unfortunately, tumors are 
seldomly confined capsules but present themselves with diffuse rims and evading tumor 
cells. Thus, a safety margin surrounding the gross tumor volume is established to avoid 
underdosing in these regions of uncertainty. Optimizing the treatment plan between a more 
confined treatment volume and adding an extensive safety margin reaching into healthy 
tissue demands an experienced radiation oncologist, careful planning and robust imaging. 
A drawback which specifically emerges in the distal safety margin, is the increase in LET 
towards the end of the proton beam path. The dose deposited by protons of an increased 
LET corresponds to a higher RBE but is widely unexplored in affected healthy cells. Thus, a 
broader understanding and possibly adaptations in treatment planning such as LET painting 
could help to minimize high-LET respectively high-RBE dose deposition into healthy tissue 
[176, 177] and circumvent this drawback of proton radiotherapy.[178] 
Importantly, the generally increased LET of proton irradiation in comparison to photon 
irradiation and these prementioned LET variations not just impose a threat to healthy tissue 
but also illustrate a promising cue for a different cellular response. Understanding biological 
differences provides clinicians with a point of leverage to target the weak points of the 
respective tumor cells. In detail, a growing body of evidence supports a different utilization 
of NHEJ and HRR, respectively, in response to photon or proton radiotherapy.  
The following section intends to outline this promising area of research and to provide a 
more detailed statement 
4.2 The role of DNA repair in response to proton radiotherapy and 
how to modulate it 
DNA repair is an important process to maintain genome integrity in unstressed but even 
more so in cells stressed by ionizing irradiation. Numerous papers investigated the 
differential recruitment of DSB repair machineries (see also 1.3.5 Repair) in response to 
photon or proton irradiation and astonishing results were obtained. 
In 2013, Grosse et al. [179] investigated the response to photon and proton irradiation in 
Chinese hamster ovary (CHO) cells with a DSB repair deficiency respectively their isogenic 
repair-proficient counterparts. Similar numbers of DSB were induced as determined by 
159 
 
immunofluorescence staining of γH2AX foci. However, cells with an HRR-deficient 
background as well as upon treatment with siRad51 were markedly hypersensitive for 
proton irradiation. These findings were confirmed in human cancer cells by Fontana et al. 
[180] who treated A549 NSCLC cells with siRad51 and additionally investigated a BRCA2-
deficient ovarian cancer cell line. Rad51 downregulation as well as BRCA2-deficiency 
resulted in hypersensitivity towards proton irradiation.  
This hypothesis of an increased relevance of HRR in response to proton irradiation was 
supported by the research group headed by Prof. Dr. Henning Willers. A screening of lung 
cancer cells for their RBE demonstrated an increased proton sensitivity in HRR-deficient cells 
while a cell line overexpressing Rad51 mRNA and protein displayed a more proton-resistant 
phenotype.[181] In addition, an increased size of 53BP1 foci was detected in HRR-deficient 
but not in HRR-proficient cell lines which was moreover limited to proton-irradiated cells. 
Further corroborating findings were provided by immortalized human fibroblasts with 
different deficiencies in HRR-relevant proteins.[182] Likewise, HRR-deficiency was linked to a 
proton-sensitive phenotype which was accompanied by an impaired removal of DSBs during 
S/G2 phase in response to proton irradiation.  
This sound evidence implies that deficiencies in HRR could act as a predictive marker for an 
increased sensitivity towards proton irradiation. Unfortunately, these deficiencies are not 
limited to tumor tissue but also present in healthy tissue as seen in BRCA1 mutation carriers. 
A mutation and/or loss of heterozygosity in the BRCA1 gene can abrogate HRR but on the 
other hand, a secondary mutation deactivating 53BP1 can restore HRR capacity. 
Conclusively, a detailed consideration of the patient and the tumor situation by the radiation 
oncologist is necessary to balance between a promising chance for clinical exploitation and a 
potentially dose-limiting factor due to side effects in healthy tissue.  
These apparent differences also illustrate that combinatorial regimens established with 
conventional photon radiotherapy cannot simply be transferred to proton radiotherapy 
without any reconsideration. On the other hand, induction of specific repair deficiencies and 
thus increasing the sensitivity for proton radiotherapy represents a promising rational similar 
to synthetic lethality. This combinatorial approach could supply radiation oncologists with an 
off-the-shelf pharmaceutical agent to increase the efficacy of proton radiotherapy. 
A number of drugs have been investigated for their role as RBE-modulating agents but 
research on proton radiobiology and especially research on drug combinations is very 
limited. Nonetheless, a promising candidate for a combinatorial approach is the histone 
deacetylase inhibitor (HDACi) SAHA.[183] SAHA sensitized A549 cells for proton and carbon 
irradiation at low concentrations and no cell cycle alterations but reduced Rad51 foci 
formation were observed. This sensitization by HDACi was limited to cancer cells and not an 
altered DNA repair but the different chromatin structure and accessibility in cancer cells 
suggested as pharmaceutical mode of action.  
Conclusively, a broader literature search was conducted to determine additional small-
molecule inhibitors with a promising pharmaceutical profile as well as an established HRR-
downregulating effect. As a result, Triapine, Gemcitabine, and Ganetespib were selected for 
further experimental research. 
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Ribonucleotide reductase (RNR) is a protein complex active during S phase and facilitates the 
synthesis of dNTP precursors.[184] Triapine inactivates RNR by quenching the catalytic 
pocket and thus stalls DNA replication and depletes the dNTP pool in proliferative cells. 
Triapine administration is conclusively linked to a decreased HRR activity and sensitizes 
tumor cells to a variety of DNA-damaging agents including cisplatin and doxorubicin. In 
addition, Triapine is of high clinical relevance and currently being investigated in a phase III 
clinical trial in combination with cisplatin and photon radiotherapy.[185] 
Gemcitabine is an already established chemotherapeutic and metabolized intracellularly to a 
dCDP analogue which also inhibits RNR.[186, 187] Gemcitabine thus depletes the dNTP pool 
and upon further phosphorylation competes with native dCTP for incorporation into DNA. As 
a result of incorporation, DNA polymerization is being terminated and replication forks 
stalled. The radiosensitizing effect of Gemcitabine is limited to HRR-proficient cell lines [188] 
and delays Rad51 foci formation but prolongs the Rad51 foci persistence in response to 
photon irradiation.[189] A suggested mechanism is the stabilization of Gemcitabine-induced 
stalled forks by BRCA2 and Rad51, the conversion into complex HRR intermediates despite 
abrogated DNA resynthetization, and the subsequent detrimental Mus81- and XPF-
dependent cleavage resulting in unrepaired DSBs.[190] A more extended recruitment of HRR 
subsequent to proton radiotherapy is therefore expected to be decelerated due to a lack of 
nucleotides and potentially provides more stalled forks than obtained by photon irradiation.  
The third drug investigated is the HSP90 inhibitor Ganetespib. Ganetespib in combination 
with DNA-damaging carboplatin but not alone induced a phenotype of global chromosome 
fragmentation.[163] HSP90 inhibition by Ganetespib downregulates key proteins of HRR 
such as FancD2 and the described phenotype could as a result be rescued by overexpression 
of FancA. Additionally, also the depletion of nuclease DNA2 prevented chromosomal 
fragmentation. This indicates a defective DNA repair in combination with uncontrolled 
nuclease activity upon combination of Ganetespib with a DNA damaging agent. Moreover, 
cell cycle checkpoint proteins such as CHK1 and Wee1 were also depleted by Ganetespib 
administration. In addition, other HSP90 inhibitors such as 17AAG are also found to 
downregulate HRR-relevant proteins such as BRCA2, Rad51, and BRCA1 and furthermore 
shifted the repair pathway choice away from HRR and towards NHEJ. [191, 192] 
To investigate the radiosensitization be the respective drug, the sublethal concentration of 
each drug was established in advance. This implies that cells continue exponential growth 
and only the combination with irradiation is severe enough to significantly reduce cellular 
proliferation. This low dosing therefore increases the relative change observed and is also 
more translatable than clinically unfeasible overdosing.  
Unfortunately, proton beam time was strictly limited and we therefore selected A549 
(wtTP53) and FaDu (mutTP53) as cell lines of interest and Ganetespib as drug of interest. 
The following section is intended to provide the context to our study and discuss supporting 




4.3 Context and clinical relevance of this study 
Firstly, research on proton radiobiology is complicated due to the highly restricted access 
and limited beam times, facilities usually being located at remote sides, and the 
understandable design for optimal patient treatment implying a lack of adjoining cell culture 
and laboratory facilities. MedAustron on the other hand provided me with the unique 
opportunity of an up-to-date pencil beam scanning proton beam, extensive lab space and 
equipment as well as support by physicists and operators. I occupied nearly all shifts 
allocated for biological research between the end of 2018 and the beginning of 2020. During 
this time, I was approached by multiple PhD-students- and PostDocs and asked on how I got 
access to a proton beam line. This illustrates that not lack of research interest but access and 
sufficient beam time are the largest limitation in current proton radiobiology as well as my 
gratitude for this privileged access.  
What also limits proton radiobiology is the far more complex physics involved in comparison 
to photon irradiation. Photons can be easily and reproducible administered by commercial 
irradiation cabinets or small-animal irradiation platforms while each proton facility is 
customized with different beam lines, different accelerators, different dose rates, and 
different set-ups for radiobiological irradiations. Proton radiobiology thus requires a more 
sophisticated experimental approach to provide robustness of results and thus comparability 
in between facilities.  
This study therefore intends to exclude as many uncertainties as feasible which is achieved 
by a water/PMMA phantom to position cell culture flasks at clinically relevant depths and 
administer proton irradiation by most advanced spot scanning. The phantom allows to place 
the slides at two positions of a SOBP and positioning can be assured by the laser alignment 
system of the treatment room. Thus, the LET and dose delivered are reproducible and mimic 
the situation in the gross tumor volume upon treatment with clinical radiotherapy. 
Our data indicated a significant increase in RBE of approximately 20% to 30% for proximal as 
well as distal SOBP protons in Ganetespib-treated A549 cells. This was confirmed in a second 
cell line and a comparable increase of RBE by 15% to 30% for proximal and distal SOBP 
protons was observed in Ganetespib-treated FaDu cells. These increases in RBE move in the 
same range as determined in HRR-deficient lung cancer cells compared to proficient cell 
lines [181] as well as by siRNA-mediated knockdown of Rad51 in A549 and CHO cells.[179, 
180]  
We are the first ones to demonstrate such a proton-specific radiosensitization by HSP90 
inhibition which is supported by data demonstrating sensitization being observed in high-LET 
carbon [193-196] but not in photon-irradiated cells.  
As described above, Rad51 requires HSP90 chaperon activity and is downregulated upon 
HSP90 inhibition.[191, 193] Despite the low doses of Ganetespib administered, a significant 
and persistent decrease in Rad51 protein levels could be observed in A549 cells. We 
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moreover demonstrated higher levels of Rad51 8h, 24, and 48h in sham-treated cells after 
proton irradiation than observed after photon irradiation.  
In accordance with previous research [179], we also determined similar numbers of γH2AX 
foci, a surrogate marker for DSBs, being induced irrespective of the administration of photon 
or proximal or distal SOBP proton irradiation. Moreover, sham-treated A549 cells exhibited a 
similar removal of γH2AX foci which was also independent of the irradiation administered 
and thus corresponds to previous findings [180, 181]. Fontana et al. described a delayed 
removal of γH2AX foci upon siRNA-mediated suppression of Rad51. In addition, also HSP90 
inhibition is indicated to reduce Rad51 foci recruitment [193] and γH2AX removal.[194, 195] 
In contrast, a reduction in Rad51 protein levels due to Ganetespib treatment as observed by 
western blotting did not alter the number of persisting γH2AX foci per nucleus and low foci 
numbers close to baseline were achieved within 24h. This implies that Rad51 levels 
remained either sufficient to facilitate HRR or missing HRR capacity was potentially replaced 
by Rad51-independent but more error-prone alternatives such as NHEJ or microhomology-
mediated end joining.[197]. This shift towards more erroneous pathways entails the risk of 
mutations or chromosomal alterations but was not further investigated in this study.  
Another not investigated mode of action of Ganetespib may be provided by cell cycle 
checkpoint proteins and their inhibition upon Ganetespib treatment. CHK1, a protein 
arresting cells in G2/M phase upon activation by ATR, is described to be downregulate by 
HSP90 inhibition.[163, 192] This abrogated G1 check point limits the time cells can utilize 
HRR and is further aggravated by premature progression into M phase and the risk of mitotic 
catastrophe and ultimately cell death. We could observe a marginally more extensive G2 
phase arrest upon proton irradiation in sham-treated A549 cells. In addition, 10nM 
Ganetespib was found to distort this post-irradiation G2 phase accumulation and 
conclusively decreased the fraction of S/G2/M phase cells. Unfortunately, due to limited 
beam time we could only obtained a duplicate of samples for A549 cells and could not 
repeat cell cycle analysis with FaDu cells. Thus, additional research and repetitions to 
investigate cell cycle accumulation, cell cycle checkpoint proteins and a potential abrogation 
of both by Ganetespib are strongly suggested.  
In conclusion, we are the first to demonstrate a reproducible and significant radiosensitizing 
effect of low dose Ganetespib in A549 and FaDu cells for clinically relevant SOBP proton 
irradiation but not for conventional photon irradiation. A potential mode of action of 
Ganetespib was determined in A549 cells by the persistent downregulation of Rad51 protein 
and a potential shift towards more error-prone DNA repair pathway. Nevertheless, beam 
time limitations prevent the repetition of western blotting, repair foci analysis and flow 
cytometry with FaDu cells as well as the conduction of more elaborate experiments to 






Proton radiobiology only represents a small niche in cancer therapy but increases in 
importance with each newly opened treatment facility. The different nature of irradiation 
implies a different pattern of damage induced as well as a different subsequent cellular 
response. Such differences bear the opportunity for clinical opportunity. In this PhD thesis, 
we demonstrated for the first time the proton-specific radiosensitization by low doses of 
HSP90 inhibitor Ganetespib. We moreover investigated the cellular response upon 
Ganetespib treatment in combination with SOBP proton and reference photon irradiation 
and suggested potential MOAs explaining the demonstrated proton-specific radio-
sensitization. 
Ganetespib and other HSP90 inhibitors are shown to specifically sensitize for carbon 
irradiation. We are the first ones to transfer this to clinically relevant SOBP proton beam 
irradiation and confirmed these findings in two cell lines. Unfortunately, a phase III clinical 
trial combining Ganetespib with Paclitaxel in NSCLC was discontinued and followed by an 
obvious decrease in research interest. A new rational for a combination of Ganetespib with 
particle therapy could renew the interest and initiate further preclinical and clinical 
investigations but the main driver of these efforts is expected to be academia. 
The determined downregulation of Rad51 protein by Ganetespib and marginally increased 
fractions of cells in S/G2 phase suggests an increased importance of HRR in response to 
proton radiotherapy and also agrees with previous findings by numerous research groups. 
We nevertheless could not define a LET dependence throughout the SOBP but also cannot 
exclude relevance at the more distal fall off region. Moreover, we cannot explain the 
indifferent repair of DNA DSBs despite Rad51 protein downregulation. 
The most important but often forgotten issue is the broad variation in experimental set-up in 
between proton treatment facilities. Conclusively, large efforts will be required to 
standardize testing and proton irradiation itself to foster the transferability of obtained 
results. We addressed this issue by mimicking the clinical situation as close as feasible and by 
detailing all physical, experimental and biological parameters.  
Research investigating combinations of chemotherapeutics and immune checkpoint 
inhibitors is faster, easier to employ, and not limited by the number of treatment facilities 
and beam time. It will therefore take huge efforts by proton radiobiologists to keep pace and 
not miss the chance of participation. 
Current immune checkpoint blockade prevents the exhaustion of immune cells but 
radiotherapy could provide the switch to activate and guide them towards the tumor. This 
perfectly illustrates the superiority of particle therapeutic approaches where immune cells 
will receive less unintended irradiation due to the more confined treatment fields and thus 
retain their potential to attack and clear tumor cells. Furthermore, the investigated HSP90 
inhibitor Ganetespib not just downregulates repair proteins but could also increase 
proteotoxic stress in a cancer-specific manner which bears the potential to provide immune 
cells with neo-antigens and improve their efficacy.  
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Summarizing, both, HSP90 inhibitors as well as proton radiotherapy, themselves represent 
promising therapeutic approaches of high clinical relevance but are neither fully understood 
nor fully exploited. 
The presented PhD work indicates that a combination of HSP90-inhibiting Ganetespib results 
in the sensitization of cancer cells specifically for proximal and distal SOBP proton 
radiotherapy. Increasing the RBE by 20% to 30% implies a huge leap in radiation oncology 
and could improve tumor control as well as patient outcome. Taken together, we generated 
reliable data that promotes the combination of proton radiotherapy with HSP90 inhibition as 
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